Clinical trial NCT05078138
Conditions: Exercise-Induced Anemia Physical Performance
Sponsor: United States Army Research Institute of Environmental Medicine
Start date: 2021-09-01; Completion date: 2023-04-01
Enrollment: 8 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
Negative hematological adaptations due to prolonged periods of strenuous physical activity may, in part, contribute to declines in physical performance during military operations. Exogenous erythropoietin (EPO) is a potential intervention that may be used to maintain hemoglobin (hgb), hematocrit (Hct), and physical performance during periods of high physical activity. The objective of the current study is to determine the ability of EPO to maintain hgb, Hct, and physical performance compared to baseline measures. Additionally, EPO may result in non-hematological adaptations which increase mitochondria biogenesis and alter substrate oxidation. As such, this study will also assess the influence of EPO on whole-body and skeletal muscle substrate oxidation. Eight healthy physically active individuals will be recruited to participate in this longitudinal trial. After exercise practice sessions, volunteers will complete baseline physical performance (time trial) and substrate oxidation testing. Participants will then receive EPO injections 3 times per week for 4 weeks. Diet and exercise will be controlled during the injection period. Participants will undergo four weeks of an intense physical training exercise program. Every seventh day during the injection period a safety blood sample, assessing hematocrit, will be drawn, and participants will complete a 5 km time trial to determine the time course of changes in physical performance can be detected. After the 4 weeks of EPO injections volunteers will complete the same physical performance and substrate oxidation testing. Substrate oxidation will be assessed during 90-min steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of VO2peak. 6-6-\[2H2\] glucose tracer technique and indirect calorimetry will be used measure substrate oxidation. Muscle biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of metabolism and inflammation before, and immediately and 3-hrs post exercise. Multiple blood samples will be collected throughout the study to determine alterations in hemoglobin, hematocrit, and markers of substrate metabolism, and inflammation. All study procedures will occur at USARIEM. The primary risks associated with this study include those associated with EPO injection, exercise, blood draws, and muscle biopsies.

Detailed description:
Healthy physically active individuals will be recruited to participate in this longitudinal trial. After baseline assessments of body composition, resting metabolic rate (RMR), VO2peak and exercise familiarization; volunteers will complete physical performance and substrate oxidation testing. Physical performance will be assessed using time trial. Substrate oxidation will be assessed by volunteers performing 90-min of steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of their VO2peak. 6-6-\[2H2\] glucose will be used as a tracer to assess glucose turnover. Indirect calorimetry will be used to determine carbohydrate and fat oxidation. Muscle biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of substrate metabolism before, immediately after, and 3-hrs post exercise. Multiple blood samples will be collected on substrate oxidation protocol days. To minimize carry over effects of muscle biopsies on subsequent exercise performance, volunteers will not exercise for 3 days. During the first two days of this period, volunteers will undergo carbon monoxide (CO) rebreathing to measure Hgb mass and blood volume. Volunteers will then receive EPO injections 3 times a week for 4 weeks. During the injection period all volunteers will have safety blood draws to assess Hct once a week. Volunteers will also complete a physical performance test once a week to determine time course change in performance with EPO compared to baseline. Exercise training will be controlled during the injection phase, consisting of a combination of endurance- and resistance-type exercise. During the final week of the injection phase body composition, resting metabolic rate (RMR) and VO2peak will be reassessed. At the end of the 4-week injection phase volunteers will complete a final physical performance test and substrate oxidation protocol, followed by two CO rebreathing tests on subsequent days. All food and beverages (except water) will be provided to volunteers beginning at the pre injection physical performance and substrate oxidation through the duration of the study. All data collection will occur at USARIEM.

Arms: arm 1: Recombinant human Erythropoietin subcutaneous injection of 50 IU/kg body mass 3 times per week for 4 week
Interventions: intervention 1: Epoetin Alfa
Intervention descriptions: intervention 1: Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks

Protocol documents:
ICF_001.pdf: 
Date: 24 August 2022  
 
1 
 
The U.S. Army Research Institute of Environmental Medicine (USARIEM) 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
 
Title of Protocol:  Erythropoietin induced hematological adaptations to enhance physical 
performance 
 
Principal Investigator:  Dr. Lee M. Margolis, PhD 
 
Introduction: You are being asked to participate in a research study because you are between 
18-39 years old with a body mass index of less than 30, are healthy, have been weight stable 
(±5 lbs) for at least two months, routinely participate in aerobic and/or resistance exercise at 
least two times a week and are representative of active duty male and female Soldiers. You do 
not have to take part in this research. It is your choice. 
 
The table below summarizes some key things to think about. After reading this summary, if you 
think you might be interested in participating, read the rest of the consent form for more details 
about the study.   
 
RESEARCH SUMMARY  
Informed 
Consent 
It is important that you understand this research study so that you can 
make an informed decision. This process is called informed consent.   
• Please ask questions about anything you do not understand.  
• Feel free to talk with your family, friends, or others before you decide. 
• After your questions have been answered, you will be asked if you 
want to participate. If you agree, you will sign this consent form. 
• You will be given a copy of this form to keep. 
Voluntary 
Participation 
You do not have to take part in this research.  It is your decision. You can 
also choose to stop participating at any time during the study. 
Purpose 
This study will allow us to understand if injections of erythropoietin (EPO), 
a hormone that makes red blood cells, improves physical performance 
during periods of high physical activity. This study will allow us to 
understand if EPO injection improves iron status and changes how your 
body uses carbohydrate, fat, and protein for energy during exercise. 
Duration 
You will be in this study for about 42 days, but may be longer based on 
your schedule. 


Date: 24 August 2022  
 
2 
 
Procedures  
While you are in the study, you will be asked to do the following: 
• 
Let us measure your height, body weight and composition 
• 
Complete 29 exercise sessions: 10 exercise testing sessions (3 
practice sessions during the baseline phase, 2 load carriage 
exercise tests, 5 time trials), 3 aerobic fitness assessments, and 
16 sessions of prescribed study exercise  
• 
Eat only food and drinks (except water) that we give you 
throughout the duration of the study 
• 
Participate only in supervised exercise training (endurance and 
resistance) that we prescribe you throughout the protocol/injection 
phase of the study (4 weeks; 16 sessions) 
• 
Keep a 3-day food record and 3-day activity log at the beginning 
of the study 
• 
Complete 12 injections of EPO (3 injections per week for 4 
weeks) 
• 
Complete 6 biopsies (3 biopsies per day for 2 days) of your thigh 
muscle, midway between your knee and hip, while under a local 
anesthetic (numbing medication)  
• 
Complete metabolism/exercise study during the testing periods 
which includes IV infusions, blood draws (26 total), breath 
collections (12 total), and exercise  
• 
Complete 4 carbon monoxide (CO) rebreathing measures 
• 
Participate in medical monitoring 
o During EPO injection phase of the study:  
 
Vital signs and health questionnaire prior to each 
scheduled exercise session  
 
Weekly safety blood draws (4 total) 
o After final EPO injection (2 week follow up): 
 
Weekly safety blood draws (2 total), daily health 
questionnaire and daily vital signs  
• 
Avoid all non-study exercise, non-study foods, smoking, use 
of nicotine-containing products, drinking alcohol throughout 
the duration of the study, and refrain from taking any NSAIDS 
(i.e. aspirin, Advil®, Aleve®, Naprosyn®, or another other 
aspirin containing product) 10 days before and at least 5 
days after each muscle biopsy. 


Date: 24 August 2022  
 
3 
 
Risks  
 
The main risks from being in this study are: 
• 
Minor discomfort and / or fainting associated with:  
o Intravenous (IV) catheter placement & blood draws 
o Subcutaneous injection 
o Muscle biopsies 
o Exercise 
o CO rebreathing (blood draw, finger stick) 
• 
Chance of infection associated with: 
o IV catheter placement & blood draws 
o Muscle biopsies 
o Place of injection site 
o CO rebreathing (blood draw, finger stick) 
• 
Potential side effects with EPO injection 
o Redness and pain at site of injection 
o Increased blood pressure 
o Blood clots 
o Joint pain 
o Nausea 
o Dizziness 
o Headaches 
o Trouble sleeping 
o Weight loss 
• 
Chance of headache associated with CO rebreathing 
Steps to lessen the risks are described later in this consent form. 
Benefits 
There is no direct health or other benefits related to participating in this 
study. Information gathered from this research may benefit other people 
in the future. 
Alternatives  
The only alternative is to not participate. 
Payment 
You will be paid for your participation in this study. 
 
 
WHY IS THIS RESEARCH BEING DONE? 
 
The purpose of this research study is to determine if injection of EPO, a hormone that makes 
red blood cells, works to maintain iron status and physical performance during periods of high 
physical activity.. This research study also aims to determine the influence of EPO on how your 
body uses carbohydrate, fat, and protein for energy during exercise. If successful, this work will 
lead to advances in biomedical strategies and solutions that safely and ethically enhance 
Warfighter physical performance in training and operational environments.   
 
WHAT WILL HAPPEN DURING THIS RESEARCH? 
 
If you agree to participate in this research, you will be a study volunteer for about 42 days 
(depending on your schedule). You will be asked to do the activities in the table below. This is 
an example schedule and the order you complete each task may vary.  


Date: 24 August 2022  
 
4 
 
 
If you agree to participate in this research, you will also be asked to follow all COVID-19 risk 
mitigation procedures in place at USARIEM during the time of data collection. You may be 
asked to wear face masks and use hand sanitizer during data collection activities (in accord with 
prevailing recommendations at the time of data collection) and may be asked to wear gloves 
(i.e. nitrile gloves) during data collection activities.  
 
Study Phase 
Duration/Activities 
Pre-Testing Baseline 
Procedures 
Up to 14 Days 
• 
Medical Screening (once for entire study, 1 hour) 
• 
Diet and Activity Records (1 record per day for 3 days) 
• 
Height measurement (1 time, 2 min) 
• 
Body weight measurement (fasted, 2 min/measurement) 
• 
Body Composition: DEXA Scan (≈10 min) 
• 
Resting Metabolic Rate (fasted, ≈1 hour) 
• 
VO2peak Aerobic Fitness Test (fasted, ≈45 min) 
• 
3 practice exercise testing sessions (fasted, 2 time trials, 1 load 
carriage, ≈1-2 hours/session) 
Baseline Physical 
Performance Testing 
and CO Rebreathing 
(Controlled Feeding) 
4 Days 
• 
5km Time Trial (fasted, ≈1 hour) 
• 
Load Carriage Exercise & Carbohydrate Tracer Study (fasted, 
≈6 hours) 
o Muscle Biopsies (3 total, ≈10 min/each) 
o Blood Sampling (8 total, ≈1 min/each) 
• 
CO rebreathing measures (2 total, ≈30 min/each) 
o Blood Sampling (2 total, ≈5 min/each) 
o Finger Sticks (2 total, ≈1 min/each) 
• 
Consume study diet 
Injection Phase 
(Controlled Feeding) 
26 Days 
• 
EPO Injection (3 times/week for 4 weeks, ≈ 5 min each) 
o The EPO being used for this protocol will be PROCRIT® 
(Janssen Products, LP, Titusville, NJ, USA), a man-
made form of human EPO 
• 
Safety blood draws (1 time/week, 4 total, ≈5 min/each) 
• 
Prescribed study exercise (4 times per week for 4 weeks) 
• 
Three 5km Time Trials (fasted, ≈1 hour/session) 
• 
Two VO2peak Aerobic Fitness Tests (fasted, about 45 min) 
• 
Blood pressure measurement (prior to each exercise session) 
• 
Health questionnaire (prior to each exercise session) 
• 
Body Composition: DEXA Scan (≈10 min) 
• 
Resting Metabolic Rate (fasted, ≈1 hour) 
• 
Three body weight measurements (fasted, 2 min/measurement) 
• 
Consume study diet  
Post Injection Physical 
Performance Testing 
(Controlled Feeding) 
and CO Rebreathing  
4 Days 
• 
One safety blood draw (≈5 min/each) 
• 
5km Time Trial (fasted, ≈1 hour) 
• 
Load Carriage Exercise & Carbohydrate Tracer Study (fasted, 
≈6 hours) 
o Muscle Biopsies (3 total, ≈10 min/each) 


Date: 24 August 2022  
 
5 
 
o Blood Sampling (8 total, ≈1 min/each) 
• 
Weight measurement (fasted, 2 min/measurement) 
• 
Consume study diet 
• 
Two CO rebreathing measures on the two subsequent days 
following performance testing (2 total, ≈30 min/each) 
o Blood Sampling (2 total, ≈5 min/each) 
o Finger Sticks (2 total, ≈1 min/each) 
Post Injection Follow 
Up 
14 Days 
• 
Two safety blood draws (1 time/week for two weeks, ≈ 5 
min/each) 
• 
Daily vital sign screening (≈2 min/each) 
• 
Daily health questionnaire (≈5 min/each) 
 
.  
 
Study Timeline 
Table 1: Study Timeline (Appendix A) 
 
Refer to the timeline located at the end of the packet.  
 
Timeline may shift based on participant availability, weekend, and holiday schedules. 
 
Screening Procedures: 
After signing the consent form, if you still wish to be in the study, you will be asked to answer 
questions about your medical history and make an appointment for a medical screening visit. 
 
Medical Screening: You will meet with the staff of the Office of Medical Support and Oversight 
(OMSO) to undergo a general medical clearance. In addition, OMSO will screen you for 
problems with blood clotting. The one-hour medical screening visit will be done at USARIEM or 
at your respective unit’s medical oversite location. You will be told about any possible medical 
concerns found from the screening by the medical staff. 
 
Health problems found during the screening process will be documented by the medical staff, 
and you will be provided a copy. You are encouraged to make an appointment with your doctor 
to follow up with a full evaluation of the identified health concerns. If you have any evidence of 
existing physical, mental and/or medical conditions that would make the proposed study more 
hazardous, you will be excluded. 
 
Study Procedures:  
Body Composition:  We will use dual energy x-ray absorptiometry (DEXA) scan to measure your 
total body, muscle, and fat mass twice during the study. For this, you will lie on your back and 
remain still for about 8-10 min while the x-ray scanner moves over your body. The DEXA will not 
cause pain or discomfort. Female volunteers will be asked to give a urine sample to test if you 
are pregnant prior to body composition scans. A female staff member will oversee the urine 
pregnancy test. 
 
Height & Weight: A researcher will measure your height and weight at baseline. Additional 
weight measurements will be taken once a week during the injection phase of the study. All 
weight measurements will be taken following an overnight fast while wearing a t-shirt and 
shorts. This will take ~ 5 min. 


Date: 24 August 2022  
 
6 
 
  
3-Day Diet and Exercise Records: Study dietitians will provide you with forms you will use to 
write down your eating and exercising habits for three days during baseline. They will show you 
how to fill out and review the forms. It should take one hour, at most, to complete them daily.   
 
Erythropoietin Injections: A sterilized needle will be used to insert a moderate dose of EPO into 
the abdominal skin 3 times per week for 4 weeks, for a total of 12 injections. Each dose will be 
about ½ teaspoon. You may notice redness and slight pain at the site of the injection, especially 
right after insertion. We will cover the injection site with a small bandaid after each injection. 
EPO injections take ~ 5 min.  
 
VO2peak (Fitness Assessment): You will perform this test on a treadmill after a 10 hr overnight 
fast to determine how well your body can use oxygen to produce energy. Following a warm-up 
you will begin running for 4-min at a comfortable pace, determined before testing starts, at a 0% 
grade.  At 4-min, the grade will be increased to 4% followed by an additional 2% every 2 min 
thereafter until you cannot run anymore. 
 
During the fitness assessment test you will wear a nose clip and breathe into a mouthpiece 
connected to a machine that measures the amount of oxygen you use and the amount of 
carbon dioxide you breathe out. You will also wear a strap around your chest to record your 
heart rate during the test. The procedure takes about 15 minutes. Measurements will be 
conducted at the beginning, middle and end of the study.    
 
Resting Metabolic Rate: Following a 10 hr overnight fast, we will measure your energy needs 
using open circuit indirect calorimetry. For this, you will lie on your back for approximately 30-
min before measurement in a quiet and dim, temperature regulated room. A hood will be placed 
over your head to collect your breath. You will be instructed to minimize movement. You will 
remain in this position with the hood on for another 20-30 minutes while measurements are 
being recorded. Measurements will be conducted at the beginning and end of the study. The 
procedure lasts a total of ~ 1 hr. This procedure can trigger claustrophobia. Individuals who 
experience claustrophobia may not wish to participate in this study.  
 
Study Diet: During the protocol phase of the study, all food and drinks (except water) will be 
prepared and given to you by study dietitians and will be largely from military combat ration and 
supplemental food items. You will be asked to return all wrappers to study dietitians. You will eat 
this diet throughout the duration of the study. No other food or beverage products (except water) 
can be consumed during this time. The different amounts of nutrients in this diet are similar to 
amounts military personnel within your age range normally eat, and will be individualized by 
study dietitians to maintain body weight.  
 
Study Exercise: During the injection phase of the study, you will participate in a supervised 
exercise training program four days a week. You will perform both weighted (treadmill; walking, 
running, and load carriage), unweighted (stationary bike) endurance type exercise, and 
resistance-type exercise throughout the injection phase of the protocol. Exercise sessions will 
range from 30-90 minutes. Exercise sessions may be broken up into a few (2-3) smaller 
sessions.  
 
Load Carriage Exercise: On these testing days you will complete 90-min of exercise on a 
treadmill carrying a load that is 30% of your body mass. During exercise, you will breathe into a 
mouthpiece connected to a machine to collect breath samples. Blood and breath samples will 
allow us to measure how your body burns carbohydrate, fat and protein for fuel during exercise. 


Date: 24 August 2022  
 
7 
 
This test will happen twice during the study. You will practice this exercise once during the 
baseline phase to become familiar with it. 
 
Carbohydrate Tracer Studies: This test will happen twice during the study and will last for 
approximately six hours. Both tests will be conducted during the load carriage exercise protocol. 
Testing will start after a 10-h overnight fast.  These studies will tell us how well your body uses 
carbohydrate as fuel during exercise when receiving EPO/PLA injections.   
 
To measure how your body uses carbohydrate we will inject a carbohydrate tracer into your 
bloodstream by an intravenous (IV) catheter placed in your arm. A second catheter will be 
placed in your other arm to collect blood samples. Blood sampling will occur eight times 
throughout the duration of this test. The tracers are a carbohydrate that is labeled with a stable 
non-radioactive isotope.  These isotopes are naturally occurring in your body and are 
considered safe.  
 
Muscle Biopsies: You will be awake during the muscle biopsies. A trained researcher will clean 
the skin with a medical cleaning solution (includes alcohol) and numb a small area of your thigh 
with a lidocaine shot (the same shots used when removing wisdom teeth), or similar product. 
The researcher will make a small cut (less than ½ inch) in the skin and use a needle to remove 
a small piece of muscle (about the size of an un-popped popcorn kernel). The researcher may 
need to use more than one needle to get a full sample. You may feel minor discomfort during a 
muscle biopsy, including some pressure (like a muscle cramp) or tugging. It should not be 
painful. You may feel a burn or sting where you get the lidocaine (or similar) shot. After the 
lidocaine (or similar) wears off, your leg may feel sore for about a week. The cuts will be 
covered with steri strips (a type of sticky bandaid), sterile gauze pad, clear sterile dressing, and 
an elastic bandage. The elastic bandage should be kept in place for 5 hours after the biopsy 
and then removed. The Principal Investigator or OMSO will remove the sterile dressing and 
gauze pad the following morning. You will be provided instructions on how to care for the biopsy 
wounds. To ensure proper healing, OMSO will follow-up with you within 72 hours after finishing 
the muscle biopsies. Biopsies will be performed on load carriage exercise days, which occur 
twice through the study. Biopsies will be taken immediately before, after, and 3-hrs post 
exercise. A total of 6 biopsies will be taken during the study. You will not exercise for 3 days 
after the biopsy. Each biopsy will take ~10 minutes.    
 
Blood Sampling: Blood samples will occur after an overnight (10 hr) fast. Blood will be collected 
using a catheter during the carbohydrate tracer studies or venipuncture for weekly safety blood 
draws and CO rebreathing. A finger stick will also be used to collect trace amounts of blood 
during CO rebreathing measures. A total of 26 (8 per carbohydrate tracer study days (16 total), 
6 per safety checks, 4 per CO rebreathing measures) blood draws will be conducted. The total 
amount of blood taken during the study will be roughly 360 ml or 1 ½  cup. Blood collected on 
carbohydrate tracer study days will be about ~ ½ cup each and ~ ½ tsp per safety draw.   
 
Breath Sampling: At various times during the load carriage exercise testing, you will wear a 
mouth piece and a nose clip, or a mask covering just your nose and mouth connected to a 
machine that measures the amount of oxygen you use and the amount of carbon dioxide you 
breathe out.  
 
Time Trial:  Following a 10-hr overnight fast, you will complete a self-paced 5km (~3 miles) time 
trail on a treadmill. The treadmill will be set at a constant 1% grade for the entire test. Following 
a warm-up period, you will blindly (you will not be able to see the display) set the speed of the 
treadmill in order to complete the distance as quickly as possible. You will be able to change the 


Date: 24 August 2022  
 
8 
 
speed as needed throughout the test. The only feedback you will be given will be distance 
covered every half mile. At each half mile, you will also be asked to rate how hard you’re 
working based on a scale provided. You will also wear a strap around your chest to record your 
heart rate after every half mile. No motivation will be provided during the time trial. You may 
drink as much water as you want during the time trial. Following completion of the test, a self-
selected cool-down will occur. You will perform this test five times throughout the protocol phase 
of the study. You will practice this exercise twice during the baseline phase to become familiar 
with it.  
 
Carbon Monoxide Rebreathing: Carbon monoxide rebreathing measures the total amount of 
hemoglobin, a specific structure in your blood that carries oxygen. Before the rebreathing 
procedure, we will collect a small amount of blood from your arm vein and fingertip. Next, you 
will breathe into a portable CO detector. To begin the rebreathing procedure, you will place your 
mouth on a spirometer (breathing device), take in a deep, slow breath to be held for 10 
seconds. While you are taking this breath, we will add a small amount 
of CO into the spirometer and open a valve allowing you to breathe 
oxygen from a small bag at the other end of the spirometer. You will 
continue to rebreathe the gases for another 1 minute and 50 seconds 
using your normal breathing pattern. After this time, you will breathe 
out as much air as you can, with the air collected into the small bag. 
After the rebreathing procedure, you will again breathe into the 
portable CO detector and we will collect blood from your fingertip. Female volunteers will be 
asked to give a urine sample to test if you are pregnant prior to each CO rebreathing 
measurement. A female staff member will oversee the urine pregnancy test.  
 
 
HOW LONG WILL I BE IN THE STUDY?  
 
The study will last a minimum of 42 days, but may last longer based on your availability. A two 
week follow up period will occur after completing the final injection. Study procedures will last 
between five minutes to six hours per visit. 
 
COVID-19 related events and study duration: In the event that research processes must be 
halted in response to a potential or confirmed COVID-19 exposure or case involving study 
participants or staff members, the study duration may be extended to accommodate the halt by 
repeating baseline measures. In the event of a COVID-19 outbreak during the injection phase, 
participants will be dropped from the research study.  
  
WHAT PRECAUTIONS DO I NEED TO TAKE? 
 
You should not perform any additional exercise outside of what you have been told to do during 
the injection phase of the study (4 weeks). You should not consume any foods or beverages 
outside of those we provide you when you are on the study diet. You should not use any 
alcohol, dietary supplements, and nicotine while on the study diet. You should not participate in 
this study if you are pregnant or breastfeeding. You should not participate in this study if you 
have Anemia and/or Sickle Cell Anemia/Trait, or a history of blood clots. You should not 
participate in this study if you are taking oral contraceptives or hormone replacement therapy 
due to increased risk of blood clotting. You should not participate in this study if you have any 
allergies or intolerances to foods (including, but not limited to lactose intolerance/milk allergy) or 
medications (including, but not limited to, lidocaine or similar) or if you are a vegetarian or 
vegan.  


Date: 24 August 2022  
 
9 
 
 
HOW MANY PEOPLE WILL BE IN THE STUDY?  
 
A total of 8 participants are needed to complete this study. We will enroll 60 individuals to 
account for dropouts. All screening will stop once complete data has been collected on 8 
participants. Though you may be eligible and want to participate, if we are able to finish data 
collection on 8 participants before you are scheduled to begin testing, you may not be tested. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?  
 
Source of Risk or 
Discomfort: 
Risk or Discomfort: 
How We Minimize Risk or 
Discomfort: 
EPO Injection 
Redness and pain at the site of 
injection, increased blood 
pressure, blood clots, joint pain, 
nausea, dizziness, headaches, 
trouble sleeping, and weight loss. 
 
Rare but possible side effects 
include: heart attack and stroke 
• 
Moderate amount for your 
body weight will be used 
(pediatric dose) 
• 
Weekly safety blood draws 
to monitor red blood cells 
and minimize risk of blood 
clots 
o 
If levels exceed 
study guidelines, 
EPO injections will 
be stopped. 
o 
Levels will be 
checked again in 3 
days. If values are 
normal you can 
return to regular 
study procedures.  
• 
Health questionnaire and 
vital signs (blood pressure, 
heart rate, oxygen 
saturation) conducted by 
study staff prior to exercise 
sessions. OMSO (licensed 
medics) will monitor and 
track copies of health 
records daily.  
• 
Continuation of vital signs 
(daily) and safety blood 
draws (1x/week) for two 
weeks following final 
injection 
Muscle Biopsies 
Rare risks included: feeling faint or 
fainting, pain, reddening of the skin, 
and bruising. 
 
Very rare risks include: infection, 
panic episode, bleeding, swelling, or 
long-term numbness. 
 
You may feel moderate stiffness and 
swelling around the cut after the 
biopsy. 
• 
You will tell study staff if you 
have ever fainted during a 
blood draw 
• 
A qualified researcher will 
perform the biopsy under 
sterile conditions to prevent 
infection or pain and close 
the cut quickly to prevent 
scarring.  
• 
You will not take aspirin or 
other medications 10 days 


Date: 24 August 2022  
 
10 
 
There might be minimal scarring as 
the cut heals and in rare cases 
permanent scars are possible. 
 
before the first biopsy or 5 
days after the last muscle 
biopsy,  
• 
You will receive biopsy care 
instructions and a qualified 
researcher will watch for any 
sign of infection, bleeding or 
bruising. 
• 
Any stiffness and/or swelling 
usually stops within days 
and does not interfere with 
walking and exercise. 
Intravenous (IV) Catheter 
Placement and Blood 
Draws 
Small risks include: feeling faint, 
irritation, bruising, swelling, 
infection, or allergic reaction  
• 
You will tell study staff if you 
have ever fainted during a 
blood draw 
• 
Trained staff will wash their 
hands, wear gloves, apply 
rubbing alcohol to the area 
and use a sterilized needle 
to place your IV.  
• 
Trained staff will watch 
closely for any signs of 
infection.  
Lidocaine (or similar) 
Shot 
Slight, brief pain and possible, rare 
side effects: You might feel a slight, 
brief pain when you get the lidocaine 
(or similar) shot. 
Rare, but possible side effects 
include: dizziness, confusion, 
shakiness, visual changes, nausea, 
unusually slow heartbeat and 
convulsions. 
Rare, but possible allergic 
reactions, include: swelling, itching, 
rash, and hives. 
• 
You will be excluded if you 
have a known Lidocaine 
allergy. 
• 
Trained staff will watch 
closely for any signs of side 
effects or allergic reactions 
during the procedure. 
• 
If you have a bad reaction to 
lidocaine, medical staff will 
be called immediately. 
Carbohydrate Tracer 
Study 
No risk or side effects w/ 
administration of stable isotopes to 
humans 
 
Small risk with infusion: volume 
overload, infection, and allergic 
reaction 
 
 
• 
Qualified pharmacists will 
prepare the injected tracers  
• 
Only qualified, credentialed 
study staff will administer 
the infusion 
• 
Infusions will be provided in 
small amounts to monitor 
the infusion 
Fitness Assessment, 
Study Exercise, Load 
Carriage Exercise and 
Time Trial  
Lightheadedness, Fatigue, 
Cardiovascular Risk, 
Musculoskeletal Strains or 
Soreness 
 
You may feel discomfort and fatigue in 
your muscles during and shortly after 
exercise. 
 
Mild to severe muscle soreness 
may continue for one to seven days. 
• 
Safety Spotters and CPR-
certified Staff 
• 
You are healthy and fit and 
will be excluded if not. 


Date: 24 August 2022  
 
11 
 
Body Composition 
 
Radiation, risk to fetus. 
 
 
• 
Low dose of radiation, the 2 
DEXA scans together equal 
the same amount of 
radiation received in a chest 
X-ray 
• 
Women who are pregnant or 
planning to become 
pregnant will be excluded 
from the study 
• 
Females will be pregnancy 
tested before 
CO-rebreathing 
Headache; see risks associated 
with blood draw 
• 
Limit test to once a day 
• 
Built-in safe guards to 
prevent too much CO 
• 
Staff supervision  
 
 
 
WHAT ARE THE POSSIBLE BENEFITS FROM BEING IN THIS RESEARCH?  
 
There is no direct health or other benefits related to participating in this study. Information 
gathered from this research may benefit other people in the future. 
 
WHAT IF UNEXPECTED INFORMATION IS LEARNED ABOUT MY HEALTH?  
 
Any health problems identified during the screening process will be documented and a copy 
provided to you. You will be encouraged to make an appointment with your primary care 
physician. 
 
WILL RESEARCH RESULTS BE SHARED WITH ME?  
  
Yes, we will be able to share results of your body composition and VO2peak tests, if requested. 
No other information will be shared. 
 
WHAT ARE MY OTHER OPTIONS IF I DO NOT PARTICIPATE IN THIS STUDY? 
 
The only alternative is not to participate in the study. 
 
WILL I HAVE TO PAY FOR ANYTHING IF I TAKE PART IN THIS RESEARCH? 
 
If you do not live on the Natick Soldier Systems Center, you will be responsible for paying for 
your transportation to and from the center. You will not be reimbursed for any travel costs or 
other costs related to participation in this research. 
 
WILL I BE PAID TO TAKE PART IN THIS RESEARCH? 
 
You will receive $50 for each successful study blood draw. There are 26 blood draws during the 
entire study. This does not include the blood sample taken during your medical clearance, which 
you will not be compensated for. If you complete all 26 study draws, you will receive 
$1300. If you do not complete the entire study, you will receive money for every successful 
blood draw you do complete. If a blood draw fails, but you complete the study, you will be paid 
in full. You will not be eligible for any other form of compensation during this study. 


Date: 24 August 2022  
 
12 
 
 
Your Social Security Number (SSN) will be needed to process your payment, as required by 
law. This information will be carefully protected. The Defense Finance and Accounting Service 
will report total payments of $600 or more within 12 months to the Internal Revenue Service 
(IRS). This may require you to claim the compensation that you receive for participating in this 
study as taxable income. 
 
WHAT HAPPENS IF I AM INJURED AS A RESULT OF TAKING PART IN THIS RESEARCH?  
 
If at any time you believe you have suffered an injury or illness as a result of participating in this 
research, please contact: 
 
 
Lee M. Margolis, PhD 
U.S. Army Research Institute of Environmental Medicine 
Building 42, Room 203A 
10 General Greene Ave 
Natick, MA 01760 
Phone Number:  508-206-2335 
Email:  lee.m.margolis.civ@health.mil 
 
If you are injured because of your participation in this research and you are a DoD healthcare 
beneficiary (e.g., active duty military, dependent of active duty military, retiree), you are entitled 
to medical care for your injury within the DoD healthcare system, as long as you remain a DoD 
healthcare beneficiary.   
 
If you are injured because of your participation in this research and you are not a DoD 
healthcare beneficiary, you are entitled to care for your injury at DoD hospitals or clinics, but 
care for your injury may be limited to a given time period, and your insurance may be billed.  It 
cannot be determined in advance which DoD hospital or clinic will provide care.  If you obtain 
care for research-related injuries outside of a DoD hospital or clinic, you or your insurance will 
be responsible for medical expenses. 
 
For DoD healthcare beneficiaries and non-DoD healthcare beneficiaries:  Transportation to and 
from hospitals or clinics will not be provided.  No reimbursement is available if you incur medical 
expenses to treat research-related injuries.  No compensation is available for research-related 
injuries.  You are not waiving any legal rights.  If you believe you have sustained a research-
related injury, please contact the Principal Investigator (PI).  If you have any questions, please 
contact the Pl (Lee Margolis and 508-206-2335). 
 
HOW WILL YOU PROTECT MY PRIVACY AND THE CONFIDENTIALITY OF RECORDS 
ABOUT ME? 
 
To protect your privacy, all of your research-related records and biological samples will be 
labeled with an assigned research participant number that will not include your name or Social 
Security Number. The link between your participant number and your research records will be 
kept in a locked cabinet or on a password-protected computer file and Dr. Lee Margolis and the 
study coordinator are the only people who have access. The master link will be destroyed upon 
study closure. Your consent form, which includes your name, but does not include a research 
participant number, will be kept separate from the rest of your research-related records in a 
locked cabinet by the principal investigator or the study coordinator.  
 


Date: 24 August 2022  
 
13 
 
Your de-identified biological samples will be stored in a designated laboratory freezer and will 
either remain at USARIEM until analysis or will be shipped to another laboratory (Metabolic 
Solutions) for later analysis. There will be no serum or plasma remaining from samples we send 
to Metabolic Solutions.  A portion of some or all of the biological samples you provide during this 
study will be frozen and retained at USARIEM indefinitely, for either re-analysis under this 
research effort or under approved, future research plans. If you do not wish your samples to be 
retained for future use by any organization that is not listed, you should not participate in this 
study. 
   
When the results of the research are published, no information will be included that would reveal 
your identity to others. Specific permission to use photographs or video recordings of you and 
the manner in which they may be used will be requested and documented in an Audio/Visual 
Image Release form. If you do not sign the photo release form, no photos of you will be taken. 
 
If any photographs or video recordings are taken of you inadvertently, they will be destroyed 
immediately. You do not have to sign a photo release to participate in this study 
 
Authorized representatives of the following groups may need to review your research and/or 
medical records as part of their responsibilities to protect research participants:  
 
• 
US Army Medical Research & Development Command Institutional Review Board 
responsible for review and oversight of human research 
• 
DoD and other Federal offices charged with regulatory oversight of human research 
• 
USARIEM Office of Research Quality and Compliance (ORQC) 
• 
The Food and Drug Administration (FDA) 
 
Once information that personally identifies you is removed from your data or specimens, then 
your data or specimens may be used for future research studies or given to other researchers 
for future research studies without your permission or future consent to do so. 
 
Complete confidentiality cannot be promised for military personnel, because information bearing 
on your health may be reported to appropriate medical or command authorities.   
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by 
U.S. Law. This web site will not include information that can identify you. At most, the Web site 
will include a summary of results. You can search this Web site at any time. 
 
 
WHAT IF I DECIDE NOT TO PARTICIPATE IN THIS RESEARCH? 
 
It is your choice whether you want to participate in this research. You can choose not to be in 
the study now or stop taking part in this research at any time without any penalty or loss of 
benefits to which you are entitled.  Deciding not to participate now or withdrawing at a later time 
does not harm, or in any way affect, your future relationships with USARIEM. You can withdraw 
by notifying the PI verbally or by writing.  If you do not complete the entire study, you will be 
compensated for the number of successful blood draws you did complete. 
 
WHAT COULD END MY PARTICIPATION IN THE RESEARCH? 
 
The investigator may withdraw you from participating in this research if: 


Date: 24 August 2022  
 
14 
 
• 
You are not willing to follow study diets and exercise prescriptions 
• 
You become ill or injured, or to protect your health and safety 
 
The investigator will make the decision and let you know if it is not possible for you to continue. 
Your taking part in the study may be stopped without your consent if it is determined by the 
investigator that remaining in the study might be dangerous or harmful to you. 
 
If you are withdrawn or decide to withdraw during the study, no further data will be collected 
from you. You will be asked to return any study food and/or wrappers that you had been 
provided. The data that has been collected from you up to that point may still be used for 
analysis. 
 
WHAT IF ANY NEW INFORMATION IS FOUND OUT?  
 
During the course of the research, the investigators will tell you of any new findings that might 
cause you to change your mind about continuing in the study.  If new information is provided to 
you, the investigators will obtain your consent to continue participating in this study. 
 
WHO SHOULD I CALL IF I HAVE QUESTIONS OR CONCERNS ABOUT THIS RESEARCH? 
 
If you have questions about the research at any time, you should contact Lee M. Margolis, PhD 
(the Principal investigator); Office phone: 508-206-2335; Email: lee.m.margolis.civ@health.mil 
 
If you have questions regarding your rights as a research participant, you may contact the HQ 
USAMRDC IRB Office at 301-619-6240 or by email to usarmy.detrick.medcom-
usamrmc.other.irb-office@mail.mil or USARIEM ORQC at phone (508-206-2371) or by email at 
usarmy.natick.medcom-usariem.mbx.usariem-rqc@health.mil   
 
 
 
 
By signing below, I agree that I have been provided time to read the information describing the 
research study in this consent form.  The content and meaning of this information has been 
explained to me.  I have been provided with the opportunity to ask questions.   I voluntarily 
consent to participate in this study.   
 
By signing this form, I have not given up any of my legal rights as a research participant. 
 
SIGNATURE OF RESEARCH PARTICIPANT  
 
________________________________________ 
Printed Name of Participant 
 
________________________________________  
______________ 
Signature of Participant 
 
 
 
 
 
Date 


Date: 24 August 2022  
 
15 
 
Appendix A: Study Timeline  
 

SAP_003.pdf: 
18 March 2025 
 
PROTOCOL TITLE:  Impact of erythropoietin on hematological adaptations and physical 
performance  
 
 
NCT: 05078138 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


18 March 2025 
 
B5.8.1  Sample Size Estimation  
Based on results for multiple outcomes across different studies (Table 1) a sample size of 8 is 
required to statistical significance.  
 
Table 1: Previous study effect sizes 
Study 
Outcome 
Delta 
Effect Size 
Sample Size 
 
 
 
 
 
Thomson et al.  
TTE 
10 ± 6 
1.40 
7 
Plenge et al.    
Hct 
5.1 ± 3 
1.56 
7 
Caillaud et al.  
CHO Oxidation 0.7 ± 0.3 
1.24 
4 
Caillaud et al.  
Fat Oxidation 
0.2 ± 0.05 
3.51 
2 
 
B5.8.2  Data analysis  
 
Statistical analyses will be conducted using either SPSS (IBM Corp. Armonk, NY), SAS 9.3 
(SAS Institute Inc., Carey, NC), or equivalent. Common descriptive statistics will be used to 
describe volunteer characteristics. Shapiro-Wilk tests will be used to determine normality of 
data. Paired t-tests will be used to assess phase effects (PRE vs. POST injection) for glucose 
turnover, and substrate oxidation. Repeated measures ANOVA will be used to assess main 
effects of time for physical performance. Mixed-model repeated measure ANOVA will be used to 
assess main effects of phase (PRE vs. POST injection), time and their interaction for blood 
analytes and muscle molecular analysis. If interactions are significant, appropriate post-hoc 
correction will be used to examine these relationships. Correlation coefficients and multiple 
regression analysis will be used to evaluate relationships between study outcome measures. 
The alpha level will be adjusted for multiple comparisons, with the level for statistical 
significance set at P < 0.05.   
 
References 
Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, Rasmussen P, Juel C, Lundby C. 
Prolonged administration of recombinant human erythropoietin increases submaximal 
performance more than maximal aerobic capacity. Eur J Appl Physiol 2007;101(4):481-
6. doi: 10.1007/s00421-007-0522-8. 
 
Caillaud C, Connes P, Ben Saad H, Mercier J. Erythropoietin enhances whole body lipid 
oxidation during prolonged exercise in humans. J Physiol Biochem 2015;71(1):9-16. doi: 
10.1007/s13105-014-0374-8. 
 
Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, 
Helge JW, Boushel R. Erythropoietin treatment enhances muscle mitochondrial capacity 
in humans. Front Physiol 2012;3:50. doi: 10.3389/fphys.2012.00050. 
 

Prot_000.pdf: 
Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 1 of 39 
PROTOCOL TITLE:  Impact of erythropoietin on hematological adaptations and physical performance  
 
SECTION A:  RESEARCH TEAM AND LOCATIONS 
 
A1.  RESEARCH TEAM 
 
Study Role 
Institution/Company and Contact Information 
Sponsor 
 
N/A 
 
Principal Investigator 
Name, Rank, and Degree: Lee M. Margolis, PhD 
Title:  Nutritional Physiologist 
Institution:  MND, USARIEM 
Address:  10 General Greene Ave Bldg. 42, Natick, 
MA 01760 
Phone Number:  508-206-2335 
Email:  lee.m.margolis.civ@health.mil 
 
Associate Investigator(s) 
 
Name and Degree: Stefan M Pasiakos, PhD 
Title:  Division Chief 
Institution:  MPD, USARIEM 
Address:  10 General Greene Ave Bldg. 42, Natick, MA 01760 
Phone Number:  508-206-2250 
Email: stefan.m.pasiakos.civ@health.mil    
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 2 of 39 
 
Name and Degree: James P McClung, PhD 
Title:  Division Chief 
Institution:  MND, USARIEM 
Address:  10 General Greene Ave Bldg. 42, Natick, MA 01760 
Phone Number:  508-206- 2240 
Email: james.p.mcclung8.civ@health.mil   
 
Name and Degree: Jess A Gwin, PhD 
Title: Nutrition Physiologist 
Institution/Company: MND, USARIEM 
Address: 10 General Greene Ave Bldg. 42, Natick, MA 01760 
Phone Number: 508-206-2300 
Email: Jessica.a.gwin.civ@health.mil  
 
Name and Degree: Emily E Howard, PhD 
Title: Nutrition Physiologist 
Institution/Company: MND, USARIEM 
Address: 10 General Greene Ave, Bldg 42, Natick, MA 01760 
Phone Number: 508-206-2309 
Email: Emily.e.howard14.civ@health.mil 
 
 
Name and Degree: Benjamin J. Ryan, PhD 
Title: Research Physiologist 
Institution/Company: TMMD, USARIEM 
Address: 10 General Greene Ave, Bldg 42, Natick, MA 01760 
Phone Number: 508-206-2408 
Email: benjamin.j.ryan14.civ@health.mil 
 
 
Project Coordinator  
 
 
 
 
 
 
Ombudsman  
 
Name and Degree: Julie Coleman, MS, RD, LDN 
Title: ORISE Research Fellow 
Institution: MND, USARIEM 
Address:  10 General Greene Ave Bldg. 42a, Natick, MA 01760 
Phone Number:  508-206-2293 
Email: julie.l.coleman5.ctr@health.mil 
 
Name, Rank, and Degree:  Katelyn Guerriere Aaron, MS 
Title:  Research Physiologist 
Institution/Company:  MPD, USARIEM 
Address: 10 General Greene Ave, Bldg 2, Natick, MA 01760 
Phone Number: 508-206-2299 
Email: katelyn.g.aaron.civ@health.mil 
Name, Rank, and Degree:  Dina M. Pitsas, MS 
Title:  ORISE Research Fellow  
Institution/Company:  TMMD, USARIEM 
Address: 10 General Greene Ave, Bldg 2, Natick, MA 01760 
Phone Number: 508-206-2380 
Email:  dina.m.pitsas.ctr@health.mil 
 
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 3 of 39 
 
A2.  ROLES AND RESPONSIBILITIES 
      
       A2.1 Principal Investigator   
 
            Name:  Lee M. Margolis 
Study Responsibilities: Dr. Margolis is responsible for the safe and scientifically sound conduct of the 
study.  He will oversee all aspects of the study, ensure safety and ethical treatment of volunteers; 
maintain required documentation for the study and obtain required approvals; and will have primary 
responsibility for data analysis, interpretation, and publication. Dr. Margolis will also be actively 
involved in the volunteer brief, obtaining consent, data collection, muscle biopsies, performing 
phlebotomy, and exercise testing. Dr. Margolis will be responsible for the conduct of the study in 
accordance with the protocol.  Maintenance of a list of appropriately qualified persons to whom 
significant study-related responsibilities have been delegated.   
 
        A2.2 Associate Investigator(s)   
 
Name(s): Stefan M. Pasiakos, James P. McClung, Jessica A. Gwin, Emily E. Howard, Benjamin J. 
Ryan  
Study Responsibilities:  Protocol development; formulation of protocol questions, hypotheses, 
experimental approach, and design. Assist PI with volunteer briefing, obtaining informed consent, 
data collection, and sample processing. Associate investigators will also ensure safety and ethical 
treatment of participants and will contribute to the analysis, interpretation, and publication of the data.   
 
 
 
       
      A2.3 Project Coordinator 
Name: Julie L. Coleman 
Study Responsibilities: Primary responsibilities include assisting with volunteer briefing, obtaining 
informed consent, data collection, preparing and administering study diets, preparing and maintaining 
data collection forms, and biological sample processing. She may conduct procedure for which she is 
qualified and credentialed as outlined in the DOA log.   
 
     A2.4 Ombudsman   
 
Name(s):  Katelyn Guerriere Aaron and Dina Pitas 
Study Responsibilities: The ombudsman shall protect the interests of the research volunteers. The 
ombudsman will do the following: read the consent form, observe the recruitment briefing and the 
signing of consent documents, make sure supervisory and command staff are not present, make sure 
the description of the study and all risks and discomforts are correct, complete, and understandable 
to the audience, and make sure that the volunteers are not threatened or pressured to participate.  
She will observe briefings for military participants in the Human Research Volunteer (HRV) program. 
 
A3.  RESEARCH LOCATIONS  
 
USARIEM, Natick MA: The U.S. Army Research Institute of Environmental Medicine (USARIEM) is a 
DoD research facility within the U.S. Army Medical Research and Materiel Command.  It is the 
Institute responsible for conducting basic and applied research to determine the effects of exposure 
to environmental extremes, occupational tasks, physical training, deployment, operational stress and 
nutritional factors on the health and performance of military personnel. The facility contains 
environmental chambers for controlling temperature and humidity, an environmentally controlled 
hypobaric chamber, a water immersion laboratory, as well as several dry and wet laboratories for 
animal and human experimentation. The dry laboratories are capable of a broad range of 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 4 of 39 
experiments, including biomechanical analysis, body composition, energy expenditure, muscle 
strength and endurance. The wet laboratories include general clinical chemistry analyzers, as well as 
equipment for ELISA, RIA, histology, and molecular biology assays.  Each investigator at the facility 
has a personal computer with software for data management, analysis, presentation and report 
generation. Their computers are interfaced with a network server for easy, secure data handling and 
transfer. All testing procedures will take place at USARIEM. 
 
Metabolic Solutions, Nashua, NH: Metabolic Solutions is a state-of-the art stable isotope analytical 
laboratory that has the basic laboratory facilities and equipment to analyze stable blood.  Equipment 
onsite includes an Agilent 6110 LC-Tandem Mass Spectrometer (LC-MS/MS) Triple Quad with 
Agilent 1100 LC, Thermo Finnigan Delta XP Isotope Ratio Mass Spectrometer (IRMS) with GC Isolink 
for 13C, 15N and 2H GC-IRMS and Conflow IV interface, and a Thermo Finnigan Delta V Advantage 
IRMS with trace GC-Combustion III unit for 13C, 15N and D GC-C-IRMS and Conflow IV interface and 
elemental Analyzer EA112HT 13C, 15N and D sample combustion unit. Metabolic Solutions has been 
an industry leader in developing new stable isotope tracer applications.  Metabolic Solutions will 
analyze samples on a fee for service basis. 
 
A4.  MULTISITE RESEARCH   
Lead Site:  N/A 
Performance Site:  N/A 
 
 
SECTION B:  RESEARCH METHODOLOGY 
 
B1.  ABSTRACT   
Negative hematological adaptations due to prolonged periods of strenuous physical activity may, in part, 
contribute to declines in physical performance during military operations. Exogenous erythropoietin 
(EPO) is a potential intervention that may be used to maintain hemoglobin (hgb), hematocrit (Hct), and 
physical performance during periods of high physical activity. The objective of the current study is to 
determine the ability of EPO to maintain hgb, Hct, and physical performance compared to baseline 
measures. Additionally, EPO may result in non-hematological adaptations which increase mitochondria 
biogenesis and alter substrate oxidation. As such, this study will also assess the influence of EPO on 
whole-body and skeletal muscle substrate oxidation.. Eight healthy physically active individuals will be 
recruited to participate in this longitudinal trial. After exercise practice sessions, volunteers will complete 
baseline physical performance (time trial) and substrate oxidation testing. Participants will then receive 
EPO injections 3 times per week for 4 weeks. Diet and exercise will be controlled during the injection 
period. Participants will undergo four weeks of an intense physical training exercise program. Every 
seventh day during the injection period a safety blood sample, assessing hematocrit, will be drawn, and 
participants will complete a 5 km time trial to determine the time course of changes in physical 
performance can be detected. After the 4 weeks of EPO injections volunteers will complete the same 
physical performance and substrate oxidation testing. Substrate oxidation will be assessed during 90-min 
steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of VO2peak. 6-6-[2H2] 
glucose tracer technique and indirect calorimetry will be used measure substrate oxidation. Muscle 
biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of 
metabolism and inflammation before, and immediately and 3-hrs post exercise. Multiple blood samples 
will be collected throughout the study to determine alterations in hemoglobin, hematocrit, and markers of 
substrate metabolism, and inflammation. All study procedures will occur at USARIEM. The primary risks 
associated with this study include those associated with EPO injection, exercise, blood draws, and 
muscle biopsies. 
 
B2.  BACKGROUND AND SIGNIFICANCE   
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 5 of 39 
Overtraining and strenuous military operations result in negative hematological adaptations, with 
hemoglobin (hgb) concentrations and hematocrit (Hct) values significantly decreased (1-4)(Figure 1). 
These negative effects have been linked to increased circulating concentrations of the pro-inflammatory 
cytokine IL-6 (5). Increased circulating IL-6 stimulates increased concentrations of the iron-regulatory 
hormone hepcidin (6, 7). Hepcidin reduces the efflux of iron into circulation by binding to and 
subsequently degrading the iron transporter protein ferroportin (8). This results in reduced absorption of 
dietary iron and release of iron from macrophages, inhibiting distribution of iron to tissues in the body (9). 
Prolonged or multiple bouts of exercise have been shown to result in greater increases of circulating IL-6 
(10, 11).  Additionally, elevated concentrations of hepcidin can persist for 24 hours post exercise (12). 
Without adequate recovery, these elevations in IL-6 and hepcidin in response to sustained performance 
of arduous physical activity results in negative hematological adaptations and potential declines in 
physical performance. Our laboratory has reported multi-day strenuous military trainings results in 
increased concentrations of circulating IL-6 and hepcidin (3, 4) and decreased hgb concentrations (3). 
These negative hematological adaptations to military training has been associated with declines in 
physical performance (1, 13). 
 
 
The negative hematological adaptations accompanying strenuous physical training can be partially 
alleviated by consuming daily iron supplements (13, 14), but hgb and Hct do not fully recover to the levels 
observed when consuming an iron supplement without performing physical training (14). This blunted 
response to iron supplementation with training is likely the result of increased hepcidin concentrations 
inhibiting absorption of dietary iron. Our laboratory recently found following a 3 day simulated military 
operation, where participants’ exercise-induced energy expenditure was ~2000 kcal/d, elevations in IL-6 
and hepcidin resulted in a ~50% reduction in iron absorption (15). These physiological consequences to 
sustained strenuous exercise led to reductions in hgb concentrations and declines in physical 
performance, despite participants consuming 22 mg/d iron, well above the recommended dietary 
allowance (RDA) of 8 mg/d for men. Results from this study suggest more robust interventions are 
required to mitigate associated negative hematological adaptations and declines in physical performance 
associated with extended periods of strenuous physical activity.  
 
Recognizing the need for more aggressive interventions to the Army has developed the Biomedical 
Performance Enhancement (BPE) program. One of the goals of this program is to identify pharmaceutical 
interventions to enhance physical performance. Exogenous erythropoietin (EPO) is one potential 
intervention that fits within the BPE program to eliminate physiological decrements during military 
operations. EPO is a hormone produced in the kidney, that stimulates erythropoiesis, production of red 
blood cells, in bone marrow (16). Stimulation of red blood cell production corrects negative hematological 
adaptations, increasing hgb concentration and Hct values (16). Exogenous EPO results in higher levels 
of hgb and Hct compared to placebo (17-19). It is important to note, exogenous EPO requires iron to 
induce erythropoiesis. Interestingly, administration of exogenous EPO with low systemic iron availability 
has been reported to reduce circulating hepcidin concentrations by an unknown mechanism, resulting in 
increased hgb and Hct (20). Furthermore, our laboratory has recently demonstrate that secondary 
elevations in circulating EPO following exogenous testosterone administration resulted in lower hepcidin 
and IL-6, and higher hgb and HCT values following 21 days of exercise-induced (~1400 kcal/d) energy 
deficits compared to placebo while consuming 18 mg/d dietary iron (21);Table 1).These finding may 
suggest that despite reduced iron efflux with overtraining, EPO may still be an effective intervention to 
maintain hgb, Hct, and physical performance. However, whether elevated IL-6 and hepcidin 
concentrations with overtraining suppress the effectiveness of exogenous EPO is unknown.  


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 6 of 39 
 
Table 1: Hematological adaptations following 21 days of energy deficit 
 
Placebo 
 
Testosterone 
 
 
Energy Balance  
Energy Deficit 
Energy Balance  
Energy Deficit 
EPO (mIU/mL) 
8.8 (7.6, 9.9)a 
8.5 (7.1, 9.8)a 
8.4 (7.2, 9.6)a 
11.3 (9.9, 12.8)b 
Hgb (g/L) 
144 (142, 147)a 
138 (136, 141)b 
145 (143, 148)a 
145 (142, 148)a* 
HCT (%) 
42.8 (42.0, 43.6)a 
41.5 (40.7, 42.3)a 
42.9 (42.1, 43.7)a 
43.6 (42.7, 44.4)a* 
Hepcidin (ng/mL) 
8.1 (6.6, 9.8)ab 
10.1 (8.5, 11.6)a 
8.6 (7.0, 10.3)a 
5.1 (3.4, 6.7)b* 
IL-6 (pg/mL) 
8.5 (6.2, 10.8)a 
10.2 (7.9, 12.5)a 
9.2 (6.9, 11.6)a 
8.5 (6.1, 10.9)a 
Values mean (95% confidence interval). Data not sharing the same letters are different; P < 0.05. 
*Different than placebo; P < 0.05. Daily exercise induced energy expenditure ~ 1400 kcal/d. 
 
 
Beyond those well characterized hematological adaptations, exogenous EPO has recently been 
discovered to result in non-hematological adaptations (22); Figure 2). Annaheim et al. (22) reported that 
changes in physical performance with exogenous EPO were independent of increases in VO2max and 
red blood cell volume. Non-hematological 
adaptations resulting in improved performance may 
be the result of molecular alterations within skeletal 
muscle. Exogenous EPO has been shown to 
increase markers of mitochondrial biogenesis (23) 
and improve mitochondrial respiratory capacity, 
increasing oxidative phosphorylation and electron 
transport capacity (24). However, while some 
investigations have reported changes in skeletal 
muscle molecular biology in response to exogenous 
EPO, there are others that have reported no effect 
on skeletal muscle (25-27). Controversy regarding 
the impact of EPO on skeletal muscle revolves 
around debate of whether an EPO receptor (EPO-R) is present at the skeletal muscle level (28, 29). The 
absence of EPO-R with skeletal muscle would indicate that there is no direct effect of EPO on skeletal 
muscle. While it is possible that EPO may not have a direct effect on skeletal muscle morphology, there 
is potential that EPO has indirect effects that result in alterations in molecular pathways regulating 
substrate oxidation within skeletal muscle. Exogenous EPO increase fat and decreases carbohydrate 
oxidation during exercise (19). Alterations in whole-body substrate oxidation during exercise are the 
result of changes in molecular regulation within skeletal muscle (30). Shifts in substrate oxidation would 
suggest that alterations do occur within skeletal muscle, if not directly, then potentially due to changes in 
hormone concentrations of O2 delivery to skeletal muscle. The influence of exogenous EPO on pathways 
regulating substrate oxidation within skeletal muscle has not been thoroughly assessed. Additionally, 
increased capacity to oxidize fatty acids and decreased reliance of carbohydrate for fuel during exercise 
with exogenous EPO likely results in sparing of muscle glycogen stores. Maintaining high muscle 
glycogen content has been well-established to improve physical performance (31). Beyond performance 
improvement, higher glycogen stores may also have additional benefit in reducing the inflammatory 
response to exercise (5). Muscle glycogen depletion following aerobic exercise results in increased IL-6 
gene expression in skeletal muscle, as well as increased circulating IL-6 concentrations compared to 
higher glycogen content (32). Potential for exogenous EPO to spare muscle glycogen and reduce post 
exercise inflammation may contribute to lower hepcidin concentrations observed with exogenous EPO 
administration described above (20).Though some work (19, 24) has been done to show alteration in 
carbohydrate and fat oxidation following exogenous EPO use, no in-depth analysis has been performed 
assessing changes in substrate oxidation at the whole body and skeletal muscle level. Specifically, no 
studies has examined the influence of EPO on glucose kinetics, glycogen storage, or the intramuscular 
molecular pathways that regulate skeletal muscle oxidation and inflammation. Furthermore, whether non-
hematological adaptations with exogenous EPO compensates for potential blunted hematological 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 7 of 39 
adaptations due to reduced iron efflux during overtraining to aid in the maintenance of physical 
performance has not been explored.     
 
B3.  MILITARY RELEVANCE    
 
 
This study supports the Military Operational Medicine Research Program’s Physiological Health and 
Performance Program Area under the BPE Work Unit. The BPE Work Unit is intent is to execute basic 
and applied research aimed at identifying and develop biomedical strategies and solutions that safely and 
ethically enhance Warfighter physical, cognitive, sensory and behavioral performance in training and 
operational environments, enabling lethality and overmatch. The proposed work aligns to the 
Physiological Health and Performance Strategic Plan Technical Challenge 1.1.1.1: Identify 
pharmacological enhancement protocols improving specific task performance under operational stress. 
 
B4.  OBJECTIVES/SPECIFIC AIMS/RESEARCH QUESTIONS 
 
Objective 
1. Determine the effects of EPO on hematological adaptions compared to baseline during 4 weeks 
of overtraining. 
 
2. Determine the time course change in physical performance (time trial) with EPO compared to 
baseline. 
 
3. Assess the influence of EPO non-hematological adaptation (whole-body and skeletal muscle 
substrate oxidation and glucose turnover) following 4 weeks of overtraining compared to baseline.  
 
Hypothesis 
1. Hemoglobin and hematocrit will be maintained with EPO during 4 weeks of overtraining. 
 
2. Physical performance will be maintained with EPO during 4 weeks of overtraining. 
 
3. EPO will increase whole body and skeletal muscle fat oxidation, and reduce reliance on 
endogenous glucose store following 4 weeks of physical training. 
 
B5.  RESEARCH PLAN    
 
       B5.1  Research Design   
 
This study will be a longitudinal trial. 
 
      B5.2  Research Subjects/Population(s) 
 
                B5.2.1  Subject Population(s)   
 
Subject population will be military or civilians representative of active duty male and female service 
members, being in good health and recreationally active.  
 
                B5.2.2  Number of Subjects, Records, and/or Specimens   
 
A total of 8 volunteers will be required to achieve sufficient statistical power. To complete testing 
on 8 volunteers, we estimate we will need to enroll 60 individuals. All screening will stop once 
complete data has been collected on 8 volunteers. Records and specimen collection are 
described in the Research Procedures and Data Collection sections. During briefings and 
consenting potential participants will be informed that even though they may be eligible and want 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 8 of 39 
to participate, if we are able to obtain enough data from preceding subjects, they may not 
ultimately be tested. These individuals may be recruited from the HRV population, civilians, and 
active duty military personnel (on the installation).    
 
               B5.2.3  Inclusion Criteria 
 
• 
Men and women aged 18 – 39 years 
• 
Weight stable (±5 lbs) for at least 2 months prior to the start of the study 
• 
Body mass index (BMI) between 18.5-30 kg/m2 
• 
Recreationally active (minimum 2-4 days per week aerobic and/or resistance exercise) 
• 
Refrain from taking any NSAIDS (i.e., aspirin, Advil®, Aleve®, Naprosyn®, or any aspirin-
containing product for 10 days before and at least 5 days AFTER each muscle biopsy. (*Tylenol® 
or acetaminophen is ok to use if needed for discomfort) 
• 
Refrain from the use of alcohol and nicotine while on study diets  
• 
Supervisor approval for federal civilian employees working within the US Army Natick Soldier 
Systems Center 
 
               B5.2.4  Exclusion Criteria 
 
• 
Metabolic or cardiovascular abnormalities, gastrointestinal disorders (i.e., kidney disease, 
diabetes, cardiovascular disease, hypertension etc.) 
• 
Personnel or family history of blood clots  
• 
Disease or medication (i.e., diabetes medications, statins, corticosteroids, etc) that affects 
macronutrient utilization and/or the ability to participate in strenuous exercise  
• 
Allergies or intolerance to foods (including but not limited to lactose intolerance/milk allergy), 
vegetarian practices, or medications (including, but not limited to, lidocaine (or similar)) to be 
utilized in the study 
• 
History of inflammatory bowel disease 
• 
History of seizures 
• 
Anemia (HCT < 38) and Sickle Cell Anemia/Trait 
• 
Abnormal PT/PTT test or problems with blood clotting  
• 
Present condition of alcoholism, use of nutritional/sports supplements, anabolic steroids, or other 
substance abuse issues 
• 
History of malignancy 
• 
Use of oral contraceptives or hormone replacement therapy due to increased risk of clotting  
• 
Musculoskeletal injuries that compromise the ability to exercise 
• 
Blood donation within 8 weeks of beginning the study 
• 
Are unwilling or unable to eat study diets and foods provided and/or follow exercise prescriptions 
• 
Pregnancy, post-partum status, or breastfeeding  
 
      B5.3  Research Procedures  
 
Research procedures conducted by investigators and support personnel will be in accordance with the 
Delegation of Authority (DOA) Log for Key Research Personnel.   
 
COVID-19 risk mitigation: Study staff and participants will comply with all COVID-19 risk mitigation 
procedures in place at USARIEM during the time of data collection.  As such, participants may be asked 
to wear face masks and use hand sanitizer during data collection activities (in accord with prevailing 
recommendations at the time of data collection) and may be asked to wear gloves (i.e., nitrile gloves) 
during data collection activities. 
 
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 9 of 39 
Study Design Overview: Healthy physically active individuals will be recruited to participate in this 
longitudinaltrial. After baseline assessments of body composition, resting metabolic rate (RMR), VO2peak 
and exercise familiarization; volunteers will complete physical performance and substrate oxidation 
testing (Figure 3). Physical performance will be assessed using time trial. Substrate oxidation will be 
assessed by volunteers performing 90-min of steady-state load carriage (30% body mass) exercise on a 
treadmill at 55 ± 5% of their VO2peak. 6-6-[2H2] glucose will be used as a tracer to assess glucose 
turnover. Indirect calorimetry will be used to determine carbohydrate and fat oxidation. Muscle biopsies 
will be performed to measure muscle glycogen, enzyme activity, and molecular markers of substrate 
metabolism before, immediately after, and 3-hrs post exercise. Multiple blood samples will be collected 
on substrate oxidation protocol days. To minimize carry over effects of muscle biopsies on subsequent 
exercise performance, volunteers will not exercise for 3 days. During the first two days of this period, 
volunteers will undergo carbon monoxide (CO) rebreathing to measure Hgb mass and blood volume. 
Volunteers will then receive EPO injections 3 times a week for 4 weeks. During the injection period all 
volunteers will have safety blood draws to assess Hct once a week. Volunteers will also complete a 
physical performance test once a week to determine time course change in performance with EPO 
compared to baseline. Exercise training will be controlled during the injection phase, consisting of a 
combination of endurance- and resistance-type exercise. During the final week of the injection phase 
body composition, resting metabolic rate (RMR) and VO2peak will be reassessed. At the end of the 4-
week injection phase volunteers will complete a final physical performance test and substrate oxidation 
protocol, followed by two CO rebreathing tests on subsequent days. All food and beverages (except 
water) will be provided to volunteers beginning at the pre injection physical performance and substrate 
oxidation through the duration of the study. All data collection will occur at USARIEM. 
 
Figure 3: Study Timeline 
 
Erythropoietin Injections (Credentialed procedure): A dose (50 IU/kg body mass) of recombinant 
human EPO (PROCRIT, EPOETIN ALFA, Janssen Products, LP, Titusville, NJ, USA) will be injected 
subcutaneously 3 times per week for 4 week. Injections will be performed by credentialed study staff at 
USARIEM. The Office of Medical Support and Oversight (OMSO) will be the prescriber of prescription 
drugs used in this protocol, to include EPO. The dosing amount and frequency is on-label dosing 
equivalent to pediatric dosing. This dose and duration has previously been shown to be sufficient to result 
in hematological adaptions and increase physical performance (18, 19, 33). Hematocrit and hemoglobin 
will be checked weekly to ensure values remain < 50%. If Hct increases above 50%, EPO injections will 
be stopped and Hct will be reassessed within 3 days. If hemoglobin increases more than 1 g/dL over a 1 
week period EPO injections will be stopped and hemoglobin will be reassessed within 3 days. 
Reticulocyte count will also be assessed on the first injection day, then again during week 2 and 4 of the 
injection phase. Additionally, before starting prescribed exercise, volunteers will complete a short 
clinically relevant health questionnaire and have vital signs checked (blood pressure, heart rate, and 
SpO2) which will take about 5 minutes by study staff. Copies of all health related information will be 
provided to the OMSO daily for review and tracking. After the final injection volunteers will continue to be 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 10 of 39 
monitored for 2 weeks by participating in weekly blood draws and daily monitoring of vital signs and 
health questionnaire which will continue to be reviewed by OMSO. Study personnel conducting this 
procedure will be credentialed and listed on the DOA log with code “F.”        
 
 
Body Composition (credential procedure): Body composition will be determined using dual energy x-ray 
absorptiometry (DEXA, DPX-IQ, GE Lunar Corporation, Madison, WI). The DEXA technique allows for 
the non-invasive assessment of soft tissue composition by region with a precision of 1-3% (34). The 
volunteer will lay face-up on the DEXA densitometer table in shorts, t-shirts, and stocking feet. Volunteers 
will be asked to remain motionless for the 8-10 min scan. These data will be used to calculate total body 
mass, fat-free mass, and fat mass. Calibration to external standards will be performed before actual data 
collection. The operator remains in the room with the volunteer during the scan. Measurements of body 
composition will be performed before and during the last week of the injection phase to characterize 
changes in fat mass and at-free mass. Female volunteers will complete a pregnancy test prior to body 
composition testing. Female staff members will oversee pregnancy tests. Study personnel conducting 
body composition scans will be credentialed and listed on the DOA log with code “U.”   
 
Height and Weights (non-credentialed procedure): Height will be measured to the nearest 0.1 cm using 
a stadiometer at baseline. Body mass will be measured after an overnight fast (≥ 8 hr), using a calibrated 
digital scale to the nearest 0.1 kg at screening. Body mass will be measured at baseline, once a week 
during the injection period. 
 
Diet and Exercise Records (non-credentialed procedure): Volunteers will complete a 3-d diet record 
(Appendix B) and a 3-d activity log (Appendix C) according to instructions provided by study team 
dietitians (35). The data will be analyzed using Food Processor SQLTM (Salem, OR Version 10.0) and the 
American College of Sports Medicine (ACSM) Compendium of Physical Activities, respectively. These 
forms will be completed at baseline to characterize volunteers’ habitual diet and exercise habits.   
 
V̇ O2peak (credentialed procedure): Following an overnight fast (10 hrs), volunteers will complete a 
maximal aerobic exercise sessions to determine peak oxygen uptake (V̇ O2peak) on a treadmill. V̇ O2peak 
will be determined using an indirect, open circuit respirator system (Parvomedics). Volunteers will be 
clothed in appropriate athletic attire and perform this assessment at standard ambient indoor temperature 
(20-22°C) and humidity conditions (30-80%). Volunteers will be given adequate time to become familiar 
with the testing procedures and allowed a 3-min self-paced warm-up on the treadmill. At the start of 
testing, the volunteer will put on a nose clip and a mouthpiece or face mask connected to a 2-way 
respiratory valve, which is attached to a head piece to hold it in place. The volunteers will begin by 
running for 4 min at a pace predetermined as comfortable at a 0% grade. At 4-min, the grade will be 
increased to 4% followed by an additional 2% every 2 min thereafter until volitional exhaustion. 
Assessment of V̇ O2peak will be done before and during the last week of the injection phase. Changes in 
V̇ O2peak after injections will be taken into account to adjust the speed and grade of the treadmill during 
steady-state load carriage exercise.   
 
Heart rate will be monitored throughout exercise using a heart-rate monitor (Polar Electro Inc, Oulu, 
Finland), and record during the last 30 seconds of each workload during all testing. The test will be 
stopped immediately if the subject reports angina-like symptoms, exertional syncope, shows signs of 
poor perfusion (i.e., light-headedness, confusion, ataxia, pallor, cyanosis, nausea, or cold and clammy 
skin), or if testing equipment fails. Study personnel conducting maximal aerobic testing will be 
credentialed and listed on the DOA log with code “J.”   
 
Resting Metabolic Rate (non-credentialed procedure): Following a 10 hr overnight fast, RMR will be 
measured using open circuit indirect calorimetry (True Max 2400, Parvomedics, Sandy, Utah, USA) at 
baseline. Volunteers will rest in the supine position for approximately 30-min before measurement in a 
quiet and dim, temperature regulated room. To minimize error, volunteers will be instructed to minimize 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 11 of 39 
movement once the hood is placed over their heads to collect expired air. The test will be discontinued 
when 20-min of steady state oxygen consumption (V̇ O2) and carbon dioxide production (V̇ CO2) are 
recorded. This measurement will be repeated during the last week of the injection phase to assess for 
changes in RMR. Baseline assessment of RMR, a factor of daily living, and Harris Benedict equation will 
be used to determine energy needs for study diets.    
 
Study Diets (non-credentialed procedure): Registered Dietitians will develop individualized daily menus 
using Food Processor SQL (ESHA Research, Salem, OR, Version 10.14). The diets will be derived 
primarily from components of the US military Meals Ready-to-Eat (MRE) rations to achieve appropriate 
macronutrient proportions. Energy content of diets during glycogen normalization will match volunteers 
estimated energy needs to maintain body weight. Volunteers will be consuming a diet providing 
approximately 55% carbohydrate, 15% protein, and 30% fat. Dietary iron will be controlled for providing a 
minimum of 18mg/day to ensure recommended dietary allowance (RDA) for both males (8mg/day) and 
females (18mg/day) is met.  
 
Time Trial (credentialed procedure): Following a 10 hr overnight fast, volunteers will complete a 5 
kilometer time trial. The treadmill will be set at a constant 1% grade (36) for the entire test. Following a 
warm-up period, volunteers will blindly modulate treadmill speed in order to complete the distance as 
quickly as possible. The only feedback given will be distance covered at half mile increments. At half mile 
increments volunteers’ rate of perceived exertion will be determined using the Borg Scale. Heart rate will 
be monitored throughout the time trial. Heart rate will be recorded at half mile increments. No motivation 
will be provided during the time trial. Participants may consume water ad libitum during the time trial. 
Following completion of the test, a self-selected cool-down will occur. Volunteers will complete a 
minimum of two practice exercise sessions to ensure they are familiar with the performance test. The 
practice sessions also will establish the coefficient of variation. Study personnel conducting maximal 
aerobic testing will be credentialed and listed on the DOA log with code “J.”     
 
Study Exercise (non-credentialed procedure): During the injection phase volunteers will conduct 
prescribed exercise training 4 days and 1 day of physical performance testing (time trial) per week. 
Volunteers will perform both weighted (treadmill or outdoor; walking, running, and load carriage) and 
unweighted (cycle ergometry) endurance-type exercise, and resistance-type exercise throughout the 
protocol. Exercise will be metabolically matched between groups, with exercise-induced energy 
expenditure being 1000-1500 kcal per day. Prescribed endurance-type exercise will be low-to-high 
intensity (30-85% V̇ O2peak) using the ACSM metabolic equations for steady-state exercise (37) and the 
compendium of metabolic equivalents for physical activities. This level of training is similar to that 
conducted during arduous military training in garrison (38). VO2peak will be assessed after 2 weeks into 
the injection phase. Exercise intensity will be adjusted based on alterations in VO2peak. Study personnel 
conducting exercise will be listed on the DOA log with code “V.”    
 
Load Carriage Exercise (non-credentialed procedure): Volunteers will complete 90-min of weighted 
steady-state exercise on a treadmill at 55 ± 5% of their VO2peak, with 30% of volunteer’s body mass. The 
speed and grade of the treadmill will be determined using the ACSM metabolic equation for walking 
based on desired V̇ O2 (39). Prior to the protocol day, participants will perform a practice session of the 
treadmill exercise to confirm the prescribed speed and grade are appropriate to induce target V̇ O2. The 
treadmill speed and grade will be maintained for both arms of the study to match the absolute workload 
of the exercise across treatments. Study personnel conducting treadmill load carriage will be listed on the 
DOA log with code “V.”   
 
Carbohydrate Tracer Study (credentialed procedure): Following an overnight (10 hour) fast, two 
catheters will be placed into the lower arm (one in each arm). One arm will be used for infusion of 6,6-
[2H2] glucose tracer and the other will be used for blood sampling. Following an initial blood sample 
collection to determine background enrichments, a primed, continuous infusion of 6,6-[2H2] glucose will 
begin (prime, 82.2 µmol∙kg-1; continuous rate, 0.78 µmol∙kg-1∙min-1, Figure 4). The 6,6-[2H2] glucose will 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 12 of 39 
be infused for 100 min under resting fasted conditions to ensure isotopic steady-state is achieved prior to 
initiating exercise. Volunteers will then perform 90 min of steady-state (~55 ± 5 % of VO2peak) load 
carriage (~30% body mass) exercise. During exercise V̇ O2, V̇ CO2, and HR will be measured 6 times at 
approximately 0, 20, 45, 60, 75, and 85 min. A total of 12 V̇ O2, V̇ CO2, and HR during the two 
carbohydrate tracer studies  Credentialed personnel performing venous catheterization will be listed on 
the DOA log with code “T.” 
 
Figure 4: Carbohydrate Tracer Study 
 
 
Percutaneous Muscle Biopsy of the Vastus Lateralis (credentialed procedure): Percutaneous muscle 
biopsies will be obtained from the vastus lateralis using a 5 mm Bergstrom needle with manual suction 
while the volunteer is under local anesthesia (1% lidocaine or similar) according to the approved 
USARIEM SOP (40, 41). Muscle biopsies will be performed immediately before, after, and post load 
carriage exercise. Each volunteer will have a total of 6 muscle biopsies during the entire study. 
Credentialed personnel performing muscle biopsies will be listed on the DOA log with code “R.”     
 
Blood Sampling (credentialed procedure): Blood samples will occur after an overnight (10 hour) fast. 
Blood collection for safety blood draws and CO rebreathing will be conducting using venipuncture. Safety 
blood draws will occur once a week during the injection (4 times) and follow-up period (2 times) of the 
protocol.  Blood will be collected using an indwelling catheter kept patent using IV saline at approximately 
-100, -20, 0, 20, 40, 60, 80, and 270 min during carbohydrate tracer studies or venipuncture for weekly 
monitoring of Hct by a USARIEM credentialed phlebotomist. Blood draws will occur once per CO 
rebreathing measure. Additionally a finger stick will be used to collect tract amounts of blood during these 
measures. A total of 26 venipuncture and IV blood draws (Appendix F) will be completed during this study 
taking ~360 mL of blood sampled from each volunteer over the protocol days (Table 2). Blood samples 
will be used for isotope analysis assessment of nutrient status, hormone responses, and inflammation 
(Table 2).   
  
For glucose kinetic analysis, the tracer/trace ratio (6,6-[2H2] glucose/glucose) will be measured on the 
pentaacetate derivative by gas-chromatography-mass spectrometry (Metabolic Solutions, Inc., Nashua, 
NH). Credentialed personnel performing venipuncture and/or venous catheterization will be listed on the 
DOA log with code “S and T.”   
 
Carbon Monoxide Rebreathing (credentialed procedure): The optimized CO-rebreathing technique (42, 
43) will be used to assess total hemoglobin mass (Hbmass, the total mass of hemoglobin in the 
circulation) and blood volume. Volunteers will sit for 20 minutes for postural control and then a venous 
blood sample will be collected to assess Hb and Hct. Baseline carboxyhemoglobin (%HbCO) will be 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 13 of 39 
assessed from an arterialized capillary blood sample (finger stick) using a hemoximeter (Radiometer, 
OSM3, Denmark, or similar). The volunteer will then breathe into a CO detector (Draeger Pac 7000, 
Draeger, Lubeck, Germany, or similar) to assess end-tidal CO. Next, the volunteer will be administered a 
bolus of CO (99.99%; men: 1.0 ml/kg body mass; women: 0.8 ml/kg body mass; if body mass index is > 
30 kg/m2 convert body mass to BMI of 25 kg/m2) into a custom built, closed-circuit spirometer (Spico-CO 
Respiration-Applikator, Blood Tec, Germany or similar) followed with 100% oxygen from a 3L bag and 
rebreathe for two minutes. Once the 2 minutes are complete, the volunteer will return to breathing room 
air. Four minutes after the initial CO inhalation, post-rebreathing end-tidal CO concentration will be 
assessed using a CO detector. Seven minutes after the initial CO inhalation, an arterialized capillary 
sample will be collected to determine the post-rebreathing increase in %HbCO. Female volunteers will 
complete a pregnancy test prior to CO rebreathing measurements. Female staff members will oversee 
pregnancy tests. Credentialed personnel performing CO rebreathing will be listed on the DOA log with 
code “W.”  
 
 
      B5.4  Data Collection   
 
 
Table 2: Carbohydrate tracer study blood analytes 
Time (min) 
 
Carbohydrate Tracer Study 
 
 
Resting 
Load Carriage Exercise 
Recovery 
Analyte 
-100 
-20 
0 
20 
40 
60 
80 
270 
Glucose1 
x 
x 
x 
x 
X 
x 
x 
 
6,6-[2H2] glucose1 
x 
x 
x 
x 
X 
x 
x 
 
Insulin2 
 
x 
x 
x 
X 
x 
x 
 
Free fatty acids2 
 
x 
x 
x 
X 
x 
x 
 
Lactate2 
 
x 
x 
x 
X 
x 
x 
 
TNFα2 
 
x 
 
 
 
 
x 
x 
IL62 
 
x 
 
 
 
 
x 
x 
Hepcidin2 
 
x 
 
 
 
 
x 
x 
C-microRNA2 
 
x 
 
 
 
 
x 
x 
Erythropoietin2 
x 
 
 
 
 
 
 
 
Archive 
x 
x 
x 
x 
X 
x 
x 
x 
 
Table 3: Carbon Monoxide Rebreathing blood analytes  
Data Element/Variable 
Source 
Operational Specification 
Anthropometric data 
Direct  measurement 
Height, weight, body composition 
Dietary intake 
Log and direct measurement 
Habitual and controlled energy, 
protein, carbohydrate, and fat intake 
Physical activity 
Log and  direct measurement 
Normal and controlled physical activity 
habits including type of exercise and 
duration 
Substrate oxidation 
Blood and breath  
Glucose turnover, carbohydrate, and 
fat oxidation 
Physical performance 
Direct measurement 
TTE  
Metabolic response 
Blood and muscle 
Blood analytes for metabolism, 
inflammation and iron status, mRNA, 
protein signaling, microRNA, activity 
assays, cross-sectional area, and fiber 
type    


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 14 of 39 
Analyte 
Pre 
Post 
HCT2 
x 
x 
HgB2 
x 
x 
Hepcidin2 
x 
x 
Ferritin2 
x 
x 
Soluble transferrin receptor2  
x 
x 
Erythroferrone2 
x 
x 
Erythropoietin2 
x 
x 
Archive 
x 
x 
Samples will be analyzed at 1Metabolic Solutions (Nashua, NH) and 2USARIEM. All blood samples will be 
separated into plasma and serum through centrifugation, aliquoted, and stored at –80˚C until analysis or 
shipment. Study samples will be collected and aliquoted at USARIEM and specific samples will be 
shipped on dry ice to Metabolic Solution. Blood sent out to other laboratories for analysis will not have 
any remaining samples after analysis is completed. USARIEM will retain all archive samples. 
 
Plasma Glucose Turnover Calculations 
For calculation of plasma glucose turnover the Steele equation with modifications for non-steady state will 
be used (44). Enrichment (E) will be expressed as mole percent excess (MPE); calculated as (TTR)/(1 + 
TTR), where TTR is the tracer to tracee ratio. Appropriate corrections for skewed abundance distribution 
and overlapping spectra will be made for the TTR of the glucose tracer, 6,6-[2H2] glucose (44).  
 
Total glucose Ra (Total Ra) = (F – ((pV x ((C2 + C1)) / 2) x ((E2 - E1) / (t2 - t1)))) / ((E2 + E1) / 2) 
Glucose Rd = Total Ra – (pV (C2 - C1) / (t2 - t1)) 
Metabolic Clearance Rate (MCR) = Glucose Rd / ((C2 + C1) / 2)   
 
Where F represents the infusion rate of 6,6-[2H2] glucose; pV is the effective volume of distribution for 
glucose, C1 and C2 are plasma glucose concentrations at t1 and t2, respectively, E1 and E2 are plasma 
enrichments of 6,6-[2H2] glucose at t1 and t2, respectively. 
 
Calculations of Carbohydrate and Fat Oxidation 
Carbohydrate, fat, and protein oxidation rates will be calculated from V̇ O2 (L/min) and V̇ CO2 (L/min) 
during the 90-min exercise bout as described by Jeukendrup and Wallis (45): 
 
Fat oxidation (g/min) = 1.695 × V̇ O2 (L/min) − 1.701 × V̇ CO2 (L/min) 
Total carbohydrate oxidation (g/min) = 4.585 × V̇ CO2 (L/min) − 3.226 × V̇ O2 (L/min). 
 
Muscle Glycogen 
Glycogen concentration will be determined using ~3 mg (dry weight) freeze dried muscle homogenized in 
water using a TissueLyser II with a 5-mm steel bead (Qiagen, Valencia, CA, USA). Homogenates will be 
boiled at 100°C for 5 min and centrifuged at 13,000×g for 5 min at room temperature. Supernatant will be 
removed and muscle glycogen concentrations will be assessed using an endpoint colorimetric assay 
(Cat# MAK016; Sigma-Aldrich, St. Louis, MO, USA).     
 
Immunohistochemistry 
Resting fasted muscle samples before and after EPO dosing will be frozen for cross-section analysis to 
include but not limited to fiber typing. Muscle sections will be stained with antibodies against either 
myosin heavy chain I or myosin heavy chain IIA. Sections will then be incubated with appropriate 
conjugated secondary antibodies for one hour at 37 °C (Alexa Fluor-568, Molecular Probes, Life 
Technologies). Fluorescent-conjugated (AlexaFluor488) Wheat Germ Agglutinin (WGA) will be used to 
stain the extracellular matrix for the calculation of fiber cross-sectional area using Image J software. 
 
mRNA, microRNA, and c-microRNA Expression 
Total RNA will be isolated using ethanol precipitation from approximately 20 mg of muscle.  Quantity and 
quality of RNA will be assessed using a Nanodrop ND-1000 spectrophotometer (Nanodrop, Wilmington, 
DE, USA).  Equal amounts of total RNA will be synthesized into cDNA for analysis of mRNA (iScriptTM 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 15 of 39 
Advanced cDNA Synthesis Kit; Bio-Rad or equivalent) and a TaqMan® microRNA RT kit (Applied 
Biosystems, Foster City, CA, USA) or equivalent. Individual Taqman® probes (Applied Biosystems) or 
microarray (Qiagen) will be used to determine the mRNA expression of intramuscular molecular 
regulation to include but not limited to, PGC-1α, PPARs, SIRT1, p53, CPT1a, FABP, FAT, TNF-α, TNF-
αR, IL-6, IL-6R, TWEAK, and TWEAK-R. microRNA analysis will be conducted using individual Taqman® 
probes (Applied Biosystems) or microarray (Qiagen), assessing microRNA that may be associated with 
metabolism and inflammation. This microRNA targets will include, but not be limited to, miR-1, miR-
23a/b, miR-26, miR-29, miR-34a, miR-103, miR-107, miR-133a/b, miR-146, miR-206, miR-208a, miR-
486, and miR-499a. 
   
Expression of microRNA will also be assessed in circulation using Taqman® probes (Applied Biosystems) 
or microarray (Qiagen). Circulating miRNA will be extracted from 200 µL serum using miRNeasy 
Serum/Plasma kit, which allows for extraction and purification of small (< 200 nucleotides) cell-free RNA 
(Qiagen or equivalent). To avoid introduction of potentially contaminating material, prior to RNA extraction 
serum samples will be centrifuged for 10 min at 4°C to remove cellular debris.  Supernatant will be 
removed and transferred to a new tube without disturbing the pellet.  Due to the small amount of RNA in 
the serum, 3.5 µL of a Spike-In Control (C. elegans miR-39; Qiagen or equivalent) will be added to all 
samples prior to extraction of RNA to determine the yield of template recovered.  After extraction 3 μl of 
serum RNA will reverse transcribed using the TaqMan® microRNA RT kit (Applied Biosystems) or 
equivalent with miRNA-specific stem-loop RT primers pooled in 1X-Tris-EDTA (TE) buffer for a final 
dilution of 0.05X.  A pre-amplification step will be performed after reverse transcription to increase cDNA 
template using a primer pool of 20 X Taqman® Small RNA Assays (Applied Biosystems) or equivalent for 
miRNA of interest at 0.05X concentration in 1X TE buffer.  All serum miRNA will be normalized to the 
geometric mean of external (Spike-In Control C. elegans miR-39) and internal controls to allow for both 
technical and inter-individual normalization (46). Geometric mean of controls will be used to correct for 
possible outlying values and abundance differences between the different controls (47).   
 
All reverse transcription for mRNA and miRNA, and pre-amplification of serum miRNA will be conducted 
in a T100TM Thermal Cycler (Bio-Rad, Hercules, CA or similar model). A StepOnePlusTM real-time PCR 
system (Applied Biosystems) or similar model will be used to perform all mRNA and miRNA analysis. 
Fold changes will be calculated using the ∆∆cycle threshold (∆∆CT) method. 
 
Bioinformatics Analysis 
microRNA with significant changes in their expression will be uploaded to DNA Intelligent Analysis 
(DIANA)-miRPath 3.0 (Alexander Fleming Biological Sciences Research Center [BSRC], Athens, Greece; 
http://diana.cslab.ece.ntua.gr) to determine potential molecular pathways that these microRNA have 
previously been reported to regulate. Relevant Kyoto Encyclopedia of Genes and Genomes (KEGG; 
http://www.genome.jp/kegg/) pathways will be identified using experimentally verified targets from 
TarBase 7.0 (Alexander Fleming BSRC). Based on findings from this analysis, any additional gene and 
protein expression of relevant targets will be assessed.    
 
Western Blotting 
Approximately 20 mg of muscle will be homogenized in ice-cold buffer (1:10 w/v) containing 50 mM Tris–
HCl (pH 7.5), 5 mM Na-pyrophosphate, 50 mM NaF, 1 mM EDTA, 1 mM EGTA, 10% glycerol (v/v), 1% 
Triton-X, 1 mM DTT, 1 mM benz-amidine, 1 mM PMSF, 10 μg mL−1 trypsin inhibitor and 2 μg mL−1 
aprotinin.  Homogenate will be centrifuged for 15 min at 10,000 × g at 4°C.  Protein concentration of 
supernatant (lysate) will be determined using 660 nm Protein Assay (ThermoFisher Scientific, Waltham, 
MA, USA or equivalent). Phosphorylation status and total protein content will be determined by Western 
blot.  Muscle lysates will be solubilized in Laemmli buffer, with equal amounts of total protein (15 μg) 
separated by SDS-PAGE using precast Tris·HCl gels (Bio-Rad). Proteins will be transferred to 
polyvinylidene difluoride (PVDF) membranes and incubated with commercially available primary 
antibodies of intramuscular molecular regulation to include but not limited to  AMPKα, p38 MAPK, PGC-
1α , SIRT1, CaMK, p53, Akt, IL-6, TNFα, NF-kB, and IKKα/β (Cell Signaling Technology, Danvers, MA, 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 16 of 39 
USA) at 4°C overnight.  Labeling will be performed using secondary antibody (anti-rabbit IgG conjugate 
with horseradish peroxidase; Cell Signaling Technology), and chemiluminescent reagent will be applied 
(Super Signal, West Pico Kit; Pierce Biotechnology, Rockford, IL, USA or equivalent). Blots will be 
quantified using the ChemiDoc XRS from Bio-Rad and Image Lab software (Bio-Rad) or similar model. 
To confirm equal protein loading per well a normalizing protein such as HSP90 or GAPDH will be 
assessed.  
 
Enzyme Activity 
Assays will be conducting using homogenate from Western blotting to include, but not limited to Pyruvate 
dehydrogenase (PDH) and citrate synthase. PDH activity will be assessed in lysates using a kinetic 
colorimetric assay (Cat# MAK183; Sigma-Aldrich). Citrate synthase activity will be determined by 
colorimetric assay combining 10 mL diluted (1:10; 0.1 M Tris HCl, pH 8.1) sample to 150 mL reaction 
master mix (1 mL DNTB [5,5-dithio-bis-(2-nitrobenzoic acid)], 3 mg acetyl-CoA, and 8 mL 0.1MTris HCl, 
pH 8.1) and 10 mL 10 mM oxaloacetate. Enzyme activity data will be normalized to run time and sample 
protein content. 
 
     B5.5  Managing Data and/or Human Biological Specimens for this Research   
 
All data and medical information obtained will be considered privileged and held in confidence. Study 
volunteers will be assigned unique subject identification (ID) numbers that will not contain any personal 
identifiers such as name, social security number, address, date of birth, zip code, etc. This study subject 
ID number will be used on all data collection instruments, to include questionnaires, data collection forms, 
computer records, etc. A number will be assigned as each volunteer is medically cleared for participation.  
A master list linking the volunteers’ names and ID numbers will be kept in a separate locked file in the 
principal investigator's office, or kept in a computer file with password-protected access restricted to the 
principal investigator. When the results of the research are published or discussed in conferences, no 
information will be included that would reveal identity. All samples will be stored using the subject 
identification number. De-identified samples for isotopic analysis will be shipped on dry ice to (blood) and 
room temperature (breath) to Metabolic Solutions. All samples will be shipped via FedEx and stored in 
these laboratories until analyzed. Once samples have been analyzed, there will be no remaining sample 
for storage other than the archived sample stored at USARIEM. Coded data will be transmitted between 
the above mentioned laboratories via an encrypted email, a secure file transfer site, or using an approved 
removable media. Only USARIEM will maintain digital copies of these data.    
 
Only the principal investigator and project coordinator will have access to personal identifiable data. No 
outside laboratory will have access to identifiable data. Hard copy data records will be stored for a 
minimum of three years from the time the study is completed. Electronic data records will be maintained 
for a period of at least ten years after the study has been completed. The master list will be destroyed 
upon the protocol’s closure. 
 
      B5.6  Managing Data and/or Human Biological Specimens for Future Research  :  
 
De-identified study samples will be stored in -80ºC freezer at USARIEM in room 322 or 304 for potential 
future use and maintained indefinitely. Only personnel assigned to the research study by the principal 
investigator will have access to samples. The de-identified data and samples will remain under the 
control of the PI and may be shared with outside collaborators for future research. Any use of the 
samples outside of this defined protocol will be submitted as a protocol amendment or a new protocol.   
.    
      B5.7  Devices, Drugs, Dietary Supplements, Nutritional Supplements, And Biologics   
 
                B5.7.1  Devices 
 
5.7.1.1 FDA-approved device being used in this research according to the approved labeling  


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 17 of 39 
 
DEXA, DPX-IQ, Lunar Corporation, True Max 2400, Parvomedics, Sandy, Utah, USA, Polar 
Electro Inc, Oulu, Finland 
 
5.7.1.2 FDA-approved device being used in this research in a manner other than its 
approved labeling: N/A 
 
                B5.7.2  Drugs 
 
                B5.7.2.1 FDA-approved and used in accordance with the approved labeling  
 
 
B5.7.2.2 FDA-approved and used in a manner not in accordance with its approved labeling:  
PROCRIT, EPOETIN ALFA, Janssen Products, LP, Titusville, NJ, USA 
 
 
                B5.7.2.3 Any drug not approved by the FDA: N/A 
 
     B5.8  Statistical Analysis 
 
               B5.8.1  Sample Size Estimation  
Based on results for multiple outcomes across different studies (Table 4) a sample size of 8 is 
required to statistical significance.  
 
Table 4: Previous study effect sizes 
Study 
Outcome 
Delta 
Effect Size 
Sample Size 
 
 
 
 
 
Thomson et al. (18) 
TTE 
10 ± 6 
1.40 
7 
Plenge et al.   (24) 
Hct 
5.1 ± 3 
1.56 
7 
Caillaud et al. (19) 
CHO Oxidation 0.7 ± 0.3 
1.24 
4 
Caillaud et al. (19) 
Fat Oxidation 
0.2 ± 0.05 
3.51 
2 
 
               B5.8.2  Data analysis  
 
Statistical analyses will be conducted using either SPSS (IBM Corp. Armonk, NY), SAS 9.3 (SAS 
Institute Inc., Carey, NC), or equivalent. Common descriptive statistics will be used to describe 
volunteer characteristics. Shapiro-Wilk tests will be used to determine normality of data. Paired t-
tests will be used to assess phase effects (PRE vs. POST injection) for glucose turnover, and 
substrate oxidation. Repeated measures ANOVA will be used to assess main effects of time for 
physical performance. Mixed-model repeated measure ANOVA will be used to assess main effects 
of phase (PRE vs. POST injection), time and their interaction for blood analytes and muscle 
molecular analysis. If interactions are significant, appropriate post-hoc correction will be used to 
examine these relationships. Correlation coefficients and multiple regression analysis will be used 
to evaluate relationships between study outcome measures. The alpha level will be adjusted for 
multiple comparisons, with the level for statistical significance set at P < 0.05.   
 
 
SECTION C:  HUMAN RESEARCH PROTECTIONS 
 
C1.  RECRUITMENT AND CONSENT   
 
       C1.1  Identification and Selection of Subjects   
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 18 of 39 
Volunteers will be recruited from the federally and non-federally employed civilian population, the Natick 
Human Research Volunteer (HRV) Pool, and NSSC active duty military personnel. 
 
       C1.2  Recruitment Process   
 
For Soldiers in the U.S. Army Natick Soldier System Center Human Research Volunteer (HRV) 
Program, the Principal Investigator will furnish a copy of the consent form to the Human Research 
Volunteer Program Coordinator or designee. The Coordinator will schedule the consent briefing for the 
HRV platoon.  
 
Superiors of Service members (e.g., unit officers, senior NCOs, and equivalent civilians) shall not be 
present at any recruitment sessions or during the consent process in which members of units under their 
command are afforded the opportunity to participate as human subjects of research. 
 
Civilian volunteers and other active duty personnel will be recruited by “word of mouth”, posted flyers 
(“off-site recruitment flyer” to be used for any flyers posted outside of NSSC, “recruitment flyer” to be 
used for postings within NSSC), or electronic distribution of the “off-site” flyer to include a text-only, 
approved version of the flyer.  Recruiting materials will be distributed around NSSC, surrounding 
community, and on bulletin boards at local universities. The text-based flyer will be posted on various 
USARIEM social media sites and used in distribution media requiring a text format (e.g., electronic 
newsletters).  Recruiting may also be conducted through briefings presented to college classes, clubs, 
sports teams, or other organizations. Approvals from the requisite parties will be obtained prior to any 
recruitment activities. 
  
Principal Investigator or Project Coordinator will receive and respond to inquiries submitted from these 
recruitment materials, and will schedule informed consent briefings for these potential volunteers. An 
ombudsman (indicated by code “L” on the DOA Log) will be present for HRV briefings. All civilian and 
non-HRV Soldier briefings will be done one-on-one. 
 
      C1.3  Eligibility   
 
Volunteers will be medically cleared by the OMSO before participation in accordance with USARIEM 
procedures outlined for screening volunteers for research involving exercise, tracer infusions, muscle 
biopsies and EPO use at USARIEM. In addition, volunteers will be screened for problems with blood 
clotting, including prothrombin time (PT)/ partial thromboplastin time (PTT), which is a specific criterion 
for research involving muscle biopsies. Health problems identified during the screening process will be 
documented and a copy provided to the volunteer. The volunteer will be encouraged to make an 
appointment with their primary care provider for a full evaluation of the problem. Volunteers with 
evidence of any physical, mental, and/or medical conditions that would make the proposed studies 
relatively more hazardous will be excluded. Any personal health information collected during this 
screening process will be destroyed at the time of study withdrawal or at the completion of the study. 
 
All volunteers must be willing to consume only food and beverages provided by study staff during the 
entire study.  Additionally, volunteers must be willing to refrain from any additional exercise during the 
study.   
 
       C1.4  Consent Process   
 
Informed consent documents will be provided to each prospective volunteer.  Additionally, an oral 
presentation will be provided to prospective volunteers by the principal investigator or his designee. In 
case of COVID risk mitigation plans, briefings can be done virtually and consent forms can be emailed 
and digitally signed. The purpose of this study, procedures involved, risks, and expectations of 
volunteers will be explained. The principal investigator or designee will answer all group and private 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 19 of 39 
questions. Potential volunteers will have a minimum of an hour, but can take longer, to review the 
consent form. Interested volunteers will sign the informed consent form prior to undergoing initial 
screening. If they meet all the medical selection criteria after completing the screening health 
assessment they will be scheduled to begin data collection. A copy of the informed consent will be 
provided to the volunteer with the original kept for study documentation. No study procedures will occur 
prior to the volunteer giving informed consent.  Volunteers who have already consented will be informed 
of any new information or changes to the protocol that may affect their willingness and ability to continue 
participation in the study using an approved consent addendum.    
 
C1.4.1  Research involving subjects with cognitive impairment or who lack capacity to 
provide informed consent 
 
N/A 
 
                 C1.4.2  Research involving non-English speaking subjects 
 
N/A 
 
C1.4.3  Research involving a waiver of the requirement to obtain informed consent OR 
alteration of the elements of informed consent  
 
N/A 
 
C1.4.4  Research involving a waiver of the requirement for investigator to obtain a signed 
consent form  
 
N/A 
 
                 C1.4.5  Waivers of assent or parental permission when the research involves children 
 
N/A 
 
                  
C2.  COMPENSATION FOR PARTICIPATION 
 
Military and civilian personnel will receive $50 for each successful blood draw. There are 26 blood draws 
during the entire study. Volunteers completing all draws will receive $1300.  If a volunteer does not complete 
the entire study, they will be compensated for the number of successful blood draws they did complete. If 
USARIEM staff fail to get a blood draw and the volunteer completes the study they will be compensated in 
full. Volunteers will not be eligible for any other form of compensation during this study.    
 
Note: Participants who receive more than $600 in a calendar year will have this income reported to the 
Internal Revenue Service. 
 
C3.  WITHDRAWAL FROM RESEARCH PARTICIPATION   
 
Volunteers will be allowed to withdraw at any time without penalty or loss of benefits to which they would 
otherwise be entitled. They will do so by informing the PI, AI or a staff member of their intent to withdraw 
verbally or in writing (electronic or paper/pencil). They will then be asked to verbally discuss their choice to 
withdraw with the PI so that reasons for withdrawal can be documented.  An investigator may stop an 
individual’s participation in the study if the volunteer is unwilling or unable to complete study procedures. An 
investigator may also withdraw a volunteer if the individual becomes ill or injured or it would not be in the 
volunteer’s best interest to continue. If the participant is withdrawn by the investigator or decides to 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 20 of 39 
voluntarily withdraw him/herself, all further data collection will discontinue. Any samples or data collected 
prior to withdrawal will be maintained. Participants will be compensated for any blood draws they completed 
up until that point, and they will be asked to return any remaining food items that were provided, in addition to 
any wrappers and diet/activity logs that they had completed up to the point of withdrawal.  
 
C4.  PRIVACY FOR SUBJECTS   
 
To protect the volunteer’s privacy, all of their research-related records will be labeled or “coded” with an 
assigned research volunteer number that will not include their name or any other form of identifiable 
information.  The principal investigator or project coordinator will keep the link between volunteer number and 
the volunteer’s research records in a locked cabinet.  Any documents that will require the volunteer’s name, 
such as the consent form, will be kept in a locked cabinet separate from any research documents that 
contain the volunteer’s ID number.  The principal investigator and project coordinator are the only people 
who will be able to match the research volunteer number with any of their personal identifying information.    
 
When the results of the research are published no information will be included that would reveal the 
volunteer’s identity to others. Photographs, videos, or audio-tape recordings of volunteers will only be used, if 
the volunteer grants permission through the Audio/Visual Image Release form. Each volunteer will also be 
asked to grant permission for his/her name to be included on his/her photo or video image or in writing 
connected to his/her image.  If a volunteer does not grant permission through the Audio/Visual Image 
Release, then no photos or other visual recordings will be taken of him/her. In the event that it is discovered 
that an individual has been inadvertently photographed or visually recorded without his/her permission, the 
materials will be immediately destroyed.  Permission through the Audio Visual Image Release form will be 
confirmed before any photographs or other visual recordings are used. 
 
C5.  CONFIDENTIALITY PROCEDURES FOR RESEARCH RECORDS, DATA, HUMAN BIOLOGICAL 
SPECIMENS   
 
Complete confidentiality cannot be promised to military participant because information bearing on the 
military participant health may be required to be reported to appropriate medical or command authorities.   
 
All data and medical information obtained will be considered privileged and held in confidence.  Study 
volunteers will be assigned unique subject identification (ID) numbers that will not contain any personal 
identifiers such as name, social security number, address, date of birth, zip code, etc.  This study subject ID 
number will be used on all data collection instruments, to include questionnaires, data collection forms, 
computer records, etc. A number will be assigned as each volunteer is medically cleared for participation.  A 
master list linking the volunteers’ names and ID numbers will be kept in a separate locked file in the principal 
investigator's office, or kept in a computer file with password-protected access restricted to the principal 
investigator and project manager. The master list linking subjects with their data will be destroyed when the 
study is closed. When the results of the research are published or discussed in conferences, no information 
will be included that would reveal identity. Study samples will be processed on site at USARIEM.  All samples 
will be stored using the subject identification number. Samples will be shipped for analysis to Metabolic 
Solutions. Remaining samples will be stored at USARIEM in a -80ºC freezer in room 322 or 304.  The 
volunteers name or other identifiable information will not be included on any data, data collection sheets, 
specimens, or other research records. De-identified samples will be maintained indefinitely. 
 
Only personnel assigned to the research study by the principal investigator will have access to the data.  
Hard copy data records will be stored for a minimum of three years from the time the study is completed.  
Electronic data records will be maintained for a period of at least ten years after the study has been 
completed.   
 
C6.  RISKS OF HARM, MEASURES TO REDUCE THE RISKS OF HARM, AND BENEFITS OF 
PARTICIPATION 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 21 of 39 
 
       C6.1 Risks of Harm  
 
Research Procedure Name:  Dual energy X-ray absorptiometry (DEXA) scan 
Research Procedure Description: Volunteer will lay face-up on the DEXA densitometer table in 
shorts, t-shirts, and stocking feet.  Volunteers will be asked to remain motionless for the 8-10 min 
scan. 
Research-related Risks:  Exposure to less than 0.6 mrem X-irradiation in a slow-speed (up to 
20 minutes) whole-body scan is possible.  This dose is equivalent to approximately 1/500 of 
normal annual background radiation (300 mrem/year), 1/6 of the radiation received in a 
transatlantic flight (3.825 mrem), or 1/3 of the radiation received in a chest X-ray (2 mrem). 
The American College of Obstetricians stated that exposure to less than 5 rem (50 mSV) has not 
been associated with an increase in fetal anomalies or pregnancy loss. 
Measures to Minimize Risks of Harm:  A quality assurance check will be completed on the DEXA 
each day prior to its use; the software will not allow the use of the DEXA densitometer if the quality 
assurance check fails. Volunteers must be advised that the health effects of very low level exposures 
to ionizing radiation, if any, are unknown (thought to be minimal). Pregnant women may not undergo 
this procedure.  Women of child bearing age must have a documented negative pregnancy test within 
the 48 hours preceding the scan. Volunteers will be cautioned against becoming pregnant while 
participating in the study. Study personnel conducting body composition will be credentialed for such 
procedures and listed on the DOA log with code “U.”   
 
Research Procedure Name:  Indwelling Catheters 
Research Procedure Description:  A needle will be used to guide a catheter into the antecubital 
vein of the volunteer. The catheter will be attached to saline to keep the line patent for multiple blood 
draws.     
Research-related Risks: The risks of blood sampling are small and usually limited to local bruising 
or swelling.  Also sometimes volunteers feel faint or may faint. If the volunteer has had problems with 
fainting during blood draws in the past, they may be more prone to them during future procedures. If 
the catheter, the tube that is left in the arm after the needle is removed, becomes clogged at any time 
during the protocol, we will have to replace this to continue blood sampling. This will require another 
needle to be inserted into your arm. In addition, the catheter can cause irritation, bruising, swelling, 
infection, or an allergic reaction. 
Measures to Minimize Risks of Harm: Trained technicians will use sterile techniques to place the 
catheter; however, in spite of being careful there is a chance that the site may become infected.  
Subjects will be briefed on the signs and symptoms of potential complications and given information 
on who to contact for medical assessment and/or treatment. Volunteers should not donate blood for 
eight weeks before or after this study. Credentialed personnel performing venous catheterization will 
be listed on the DOA log with code “T.”   
 
Research Procedure Name: 6,6-[2H2] glucose infusions  
Research Procedure Description: 6,6-[2H2] glucose will be infused using a indwelling catheter. 
Research-related Risks: The primary risks associated with tracer studies are those related to 
venous catheterization. The catheter can cause irritation, bruising, or infection. There are no known 
risks or reported side effects associated with administration of 6,6-[2H2] glucose infusions to humans 
during clinical or experimental studies. The risks associated with the infusion include volume 
overload, infection, and allergic reaction to the infused substance. There have been no occurrences 
of volume overload, no occurrences of infection or allergic reaction attributable to iodine used prior to 
venipuncture in any of the 200 infusion protocols that the investigators have been involved. To 
minimize the likelihood of these events occurring, infusion rate will be closely monitored and 
maintained at less than 30 ml/hr throughout the entire infusion protocol day. 
Measures to Minimize Risks of Harm: All staff who directly participate in the infusion studies will be 
properly trained how to safely monitor (i.e., infusion pumps and IV lines) infusion studies from Dr. 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 22 of 39 
Margolis, who has extensive experience with infusion studies. In addition, infusates will be prepared 
sterile, pyrogen-free, and in the proper dosages by a licensed pharmacist. If sign of allergic reaction, 
rash or redness, infusion will be stopped immediately. Credentialed personnel performing venous 
catheterization will be listed on the DOA log with code “T.” 
 
Research Procedure Name:  Venipuncture 
Research Procedure Description: A needle will be used for single blood draws of the antecubital 
vein.   
Research-related Risks:  Venipuncture is a routine clinical procedure the medical community 
commonly uses to obtain blood samples. The immediate complications may be slight pain during the 
entry of the needle into the skin, possible dizziness, and syncope. Dizziness or syncope constitutes 
no long-term harm, and immediate relief is achieved by having the subject put their head down 
between their knees or lie down. Additionally, a hematoma may result from the venipuncture, but this 
is more unsightly than risk producing. Late complications might include thrombosis of the vein due to 
trauma or infection. These complications are extremely rare. 
Measures to Minimize Risks of Harm: Participant monitoring, aseptic technique, including sterile 
disposable blood collection apparatus and adherence to standard medical precautions reduce risk.  
Trained technicians will perform all venipuncture. Subjects will be briefed on the signs and symptoms 
of potential complications and given information on who to contact for medical assessment and/or 
treatment. Credentialed personnel performing venipuncture will be listed on the DOA log with code 
“S.”   
 
Research Procedure Name:  Exogenous EPO 
Research Procedure Description:  A needle and syringe will be used to inject prescribed EPO 
amounts subcutaneously in the abdomen 3 times a week for 4 weeks.  
Research-related Risks: Side effects with EPO injection are redness and pain at the site of injection, 
increase blood pressure, blood clots, joint pain, nausea, dizziness, headaches, trouble sleeping, and 
weight loss. Rare but possible side effects can include myocardial infarction and stroke  
Measures to Minimize Risks of Harm: To minimize side effects the study will use a low dose EPO 
injection equivalent to a pediatric dose. Before participants begin the prescribed exercise they will 
complete a short clinically relevant health questionnaire (Appendix A) and have their vital signs 
(blood pressure, heart rate, and SpO2) assessed by study staff. Copies of all health related 
information will be provided to OMSO daily for review and tracking. Hemoglobin and Hct values will 
be measured weekly during EPO injections. To minimize risk of blood clots Hct values will be 
maintained < 50%. If Hct values increase > 50% EPO injections will be stopped. Volunteer will return 
to for another Hct check within 3 days.  If hemoglobin increases more than 1 g/dL over a 1 week 
period EPO injections will be stopped and hemoglobin will be reassessed within 3 days. EPO 
injections will only be administered by credentialed staff at USARIEM. These individuals will follow 
administration procedures provided in the PROCRIT® prescriber information guide. Volunteers will 
continued to be monitored for 2 weeks after the injections are complete to ensure there are no 
complications from the EPO injections. The OMSO will be responsible for observing and monitoring 
adverse events of participants in this study.  
 
Research Procedure Name:  Exercise 
Research Procedure Description:  Exercise testing will occur on a cycle ergometer or treadmill.  
Exercise will be at various levels of intensity based on exercise protocol. 
Research-related Risks:  Exercise per se rarely provokes cardiovascular events in healthy 
individuals with normal cardiovascular systems.  The prevalence of fatal events in the U.S. is 
approximately 1:133,000 to 1: 185,000 for men and 1:769,000 to 1:1,500,000 for women who are 
competitive high school and college athletes. For middle-aged and older adults the relative risk rises 
to 1:15,000 to 1:18,000 for individuals without a prior history of cardiovascular events. Current civilian 
and military guidelines state that individuals less than 40 years of age who have no symptoms of or 
known presence of heart disease or major coronary risk factors have a low risk for cardiac 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 23 of 39 
complications during vigorous exercise.  All volunteers in this study fall into this low risk category.  
Local muscle discomfort and fatigue may occur in active muscles during and shortly after exercise.  
Muscle soreness, ranging in intensity from mild to severe, may persist for 1 to 7 days.  
Measures to Minimize Risks of Harm: (Precautions, safeguards):  Studies have confirmed the 
safety of maximal exercise testing, particularly among apparently healthy persons without significant 
cardiovascular risk factors.  As a precaution, there will be at least one spotter during all exercise 
sessions, and heart rate will be monitored in real time during testing.  In addition, exercise monitors 
and test administrators will be CPR-certified. Study personnel conducting maximal aerobic testing 
and treadmill load carriage will similarly be credentialed for such procedures and listed on the DOA 
log with code “V.”   
 
Research Procedure Name: Percutaneous Skeletal Muscle Biopsy 
Research Procedure Description: A small incision will be made in the skin and fascia of the vastus 
lateralis. A 5-mm Bergstrom biopsy needle will pass through these incisions with manual suction 
applied to collect muscle samples, while the volunteer is under local anesthesia (1% lidocaine or 
similar local anesthetic analogue in dosages and composition approved by OMSO). 
Research-related Risks: Percutaneous needle muscle biopsies have been established as a non-
routine, but safe research procedure. Similar to blood draws, there is a risk that volunteers will feel 
faint or may faint right after a muscle biopsy. If the volunteer has had problems with fainting during 
blood draws or muscle biopsies in the past, they may be more prone to them during future 
procedures. The most common risks associated with muscle biopsies are pain (~1.27%), erythema 
(~1.27%), and ecchymosis (1.27%) (48, 49). Panic episode, bleeding, and edema have also been 
reported (0.21%, 0.42%, and 0.84%, respectively) (48). Denervation, numbness, and atrophy may 
occur but have not been verified in the literature. Some minimal scarring will accompany healing of 
the incision and formation of a hypertrophic scar or keloid is possible. Although this is a rare event in 
fair-skinned persons, the incidence of hypertrophic scarring or keloid formation associated with 
healing of a primarily closed skin biopsy site (i.e., one which was closed with sutures immediately 
afterward) is 5-10% in dark-skinned persons.  
Measures to Minimize Risks of Harm: Lidocaine (or similar anesthetic) will be used to minimize 
pain or discomfort. Potential risk for complications of bleeding will be reduced by applying direct 
pressure to the wound following the biopsy. If soreness symptoms should occur, they usually do not 
interfere with normal walking or heavier exercise. Volunteers with evidence of bleeding diathesis 
should be excluded during medical clearance; those with local skin infection or irritation or recent use 
of anticoagulant medication not identified during initial medical screening (including aspirin) will be 
withdrawn by the PI in consultation with OMSO. Volunteers will be instructed about precautions 
against hematoma and infection. Volunteers will refrain from non-steroidal anti-inflammatory 
medications for 10 days before and 5 days after the muscle biopsies. They will be given a handout 
outlining instructions for proper care of the incision site (Appendix C). Muscle biopsies will be 
performed using sterile procedures and equipment by study staff members who are credentialed to 
perform skeletal muscle biopsies and who will abide by USARIEM’s Percutaneous Skeletal Muscle 
Biopsy SOP (OMSO-approved USARIEM SOP for Invasive Procedures, Chapter 10) of 11 July 2017 
in all regards. Either Dr. Margolis, other credentialed individual who performed the muscle biopsy  
and OMSO will follow-up with volunteers within 3 d post-biopsy to monitor for any sign of infection, 
bleeding, or hematoma. Study personnel conducting muscle biopsies will be credentialed for such 
procedures and listed on the DOA log with code “R.”   
 
Research Procedure Name: Lidocaine (or similar) Injection 
Research Procedure Description: Approximately 8-10 mL of 1% lidocaine (or similar local 
anesthetic analogue in dosages and composition approved by OMSO) will be injected using a 25 g 
needle at the site of the incision, superficially (i.e., skin) and within the vastus lateralis. 
Research-related Risks: Slight pain at the site of injection might occur. Although rare, anaphylactic 
reactions may also occur following administration of lidocaine (or similar). Unlikely, but possible side 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 24 of 39 
effects could include: dizziness, confusion, shakiness, visual changes, nausea, and unusually slow 
heartbeat.  
Measures to Minimize Risks of Harm: Volunteers will be screened for all allergies during the initial 
general medical clearance. Volunteers will be instructed to notify a Study Investigator or any staff 
member immediately if an allergic (i.e., swelling, itching, rash, hives, difficulty swallowing, or difficulty 
breathing) reaction occurs. In the case of severe reaction, OMSO will be notified immediately and 
lidocaine (or similar) use will be discontinued and if indicated emergency medical staff will be 
contacted. In the event of an extremely severe reaction, an Epinephrine Auto-Injector will be available 
onsite. Only credentialed PIs will administer the lidocaine (or similar), and medical staff will be on 
duty. 
 
Research Procedure Name: Optimized CO-rebreathing 
Research Procedure Description: CO-rebreathing has been safely used to assess Hbmass for over 
100 years. In this procedure the volunteer will inhale a bolus of CO (99.99%,; men: 1.0 ml/kg body 
mass; women: 0.8 ml/kg body mass; if body mass index is > 30 kg/m2 convert body mass to BMI of 
25 kg/m2) followed with 2 minute rebreathing 100% oxygen (from a 3L bag) using a closed circuit 
spirometer (Spico-CO Respiration-Applikator, Blood Tec, Germany or similar). Arterialized capillary 
blood (finger-tip) will be collected at the beginning of the rebreathing procedure and after seven 
minutes of the initial CO inhalation to assess blood %HbCO. Sodalime will be used to prevent 
accumulation of CO2.   
Research-related Risks: Minor risk of performing the optimized CO-rebreathing procedure include 
headache (extremely rare). Additionally, finger-sticks may result in pain, dizziness, fainting, infection, 
bruising, tenderness, and/or edema at puncture site, skin irritation, nausea and vomiting. It is 
unknown what potential risks might be present for pregnant women, so those who are pregnant will 
be excluded from participation. 
Measures to Minimize Risk of Harm (Precautions, safeguards): This method uses a small, 
quantified volume of CO aimed at increasing the %HbCO by 4-7% above baseline. CO-rebreathing 
will not be performed if baseline %HbCO is >3%, thus reducing the likelihood of headache. 
Additionally, only one CO-rebreathing procedure will be completed per day. Study staff will also 
monitor volunteers. Finger capillary sticks will be performed by credentialed and proficient research 
personnel who will use aseptic technique. Risk of fainting or dizziness will be minimized by having 
subjects seated during blood draws/fingersticks. Female volunteers will self-administer a pregnancy 
test prior to undergoing CO rebreathing tests. 
 
      C6.2  Incidental or Unexpected Findings  
 
Health problems identified during the screening process will be documented and a copy provided to 
the volunteer. The volunteer will be encouraged to make an appointment with their primary care 
provider for a full evaluation of the problem. Volunteers with evidence of any physical, mental, and/or 
medical conditions that would make the proposed studies relatively more hazardous will be excluded. 
 
      C6.3  Potential Benefits  
 
There is no direct health or other benefits related to participation in this study.  Information gathered 
from this research may benefit other people in the future. 
 
C7.  DATA AND SAFETY MONITORING   
 
       C7.1 Monitoring  
 
The Principal Investigator will be responsible for monitoring the data collected. The Principal Investigator, 
with the assistance of the Study Coordinator, will ensure that the data is being collected according to the 
methods described in the protocol. Electronically collected data will be downloaded daily and checked for 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 25 of 39 
quality. This also includes continuous evaluation of th/e following: recruitment, the informed consent 
process, adverse events, protocol adherence, and protocol deviations. This will occur continuously in 
order to identify unanticipated problems or risks to the volunteers associated with the research. The 
Principal Investigator will ensure that the number of volunteers recruited for this study complies with the 
protocol. If adverse events occur, the Principal Investigator will submit a monthly summary of the related 
adverse events to OMSO to determine whether the number of adverse events is excessive for the risks 
outlined in the research protocol. The Principal Investigator and Study Coordinator will be responsible for 
ensuring that the appropriate regulatory and IRB documentation is on file and up to date. 
 
C8.  REPORTABLE EVENTS    
 
       C8.1  Expected adverse events  
 
An adverse event is defined as any untoward or unfavorable medical occurrence in a human research 
participant, including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, 
or disease, temporally associated with the individual’s participation in the research, whether or not 
considered related to the individual’s participation in the research. 
 
Expected adverse events are local bruising and soreness from blood draws and at the site of EPO 
injections, and muscle soreness or pain from exercise. Expected adverse events for muscle biopsies are 
local soreness, redness, or bruising. Expected adverse events which are not serious are reported to the 
IRB at the time of continuing review of the protocol.   
 
 
All medical events that the USARIEM Office of Medical Support and Oversight (OMSO) evaluates will be 
reported to the ORQC.  
 
       C8.2  Unexpected adverse events and unanticipated problems 
 
A serious adverse event is any adverse event temporally associated with the subject’s participation in 
research that is fatal, life-threatening, permanently disabling, requires inpatient hospitalization, or results 
in congenital anomalies/birth defect, overdose or cancer, or based on appropriate medical judgment, 
may jeopardize the participant, or may require medical or surgical intervention to prevent one of the 
above outcomes. 
  
All medical events will be reported to USARIEM’s Office of Medical Support and Oversight (OMSO). 
OMSO staff will retain a copy of the report in the subject’s OMSO medical file as a means of tracking 
and analyzing trends in medical events.   
 
All unanticipated problems involving risk to subjects or others, serious adverse events that are 
unexpected and determined to be at least possibly or definitely related to study participation, will be 
promptly reported within one working day by phone (508-206-2371/2200) or email 
(usarmy.natick.medcom-usariem.mbx.usariem-rqc-protocol@health.mil) to the USARIEM ORQC  and 
the Commander.  These events will also be reported to the HQ USAMRDC IRB within one working day 
by phone (301-619-6240), or by e-mail (usarmy.detrick.medcom-usamrdc.other.irb-office@mail.mil)  
 
Adverse events assessed by the PI as not serious and serious adverse events that are deemed to be 
unrelated to participation in the study will be reported to the IRB at the time of continuing review of the 
protocol.   
 
 
In the event of a medical emergency at facilities on the Natick Soldier Center, the local Emergency 
Medical Services (EMS) will be contacted immediately by dialing 5911. The installation security 
personnel will direct the ambulance to the proper location on the installation.  While awaiting their arrival, 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 26 of 39 
Basic Life Support will be rendered by study personnel or on-site medical coverage. EMS response time 
to USARIEM is approximately 5 minutes.   Transport time to definitive care is approximately 8 minutes. 
 
       C8.3  Adverse device effects 
 
N/A 
 
       C8.4  FDA-regulated research under IND and IDE 
 
The investigation is not intended to be reported to the FDA as a well-controlled study in support of a new 
indication of use or any other significant labeling or advertising for the drug. The investigation will be 
conducted in compliance with the requirements for institutional review per 21 CFR Part 56 and the 
requirements for informed consent per 21 CFR Part 50. The drug will not promoted as safe or effective and 
the study will be conducted in compliance with 21 CFR Part 312.7.  
 
 
SECTION D:  REFERENCES 
 
Reference List 
 
1. 
McClung JP, Karl JP, Cable SJ, Williams KW, Young AJ, Lieberman HR. Longitudinal decrements in iron status 
during military training in female soldiers. Br J Nutr 2009;102(4):605-9. doi: 10.1017/S0007114509220873. 
2. 
Merkel D, Huerta M, Grotto I, Blum D, Rachmilewitz E, Fibach E, Epstein Y, Shpilberg O. Incidence of anemia 
and iron deficiency in strenuously trained adolescents: results of a longitudinal follow-up study. J Adolesc 
Health 2009;45(3):286-91. doi: 10.1016/j.jadohealth.2009.02.003. 
3. 
McClung JP, Martini S, Murphy NE, Montain SJ, Margolis LM, Thrane I, Spitz MG, Blatny JM, Young AJ, 
Gundersen Y, et al. Effects of a 7-day military training exercise on inflammatory biomarkers, serum hepcidin, 
and iron status. Nutr J 2013;12(1):141. doi: 10.1186/1475-2891-12-141. 
4. 
Pasiakos SM, Margolis LM, Murphy NE, McClung HL, Martini S, Gundersen Y, Castellani JW, Karl JP, Teien 
HK, Madslien EH, et al. Effects of exercise mode, energy, and macronutrient interventions on inflammation 
during military training. Physiol Rep 2016;4(11). doi: 10.14814/phy2.12820. 
5. 
Hennigar SR, McClung JP, Pasiakos SM. Nutritional interventions and the IL-6 response to exercise. FASEB 
journal : official publication of the Federation of American Societies for Experimental Biology 2017;31(9):3719-
28. doi: 10.1096/fj.201700080R. 
6. 
Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, 
and plasma cytokine levels in humans injected with LPS. Blood 2005;106(5):1864-6. doi: 10.1182/blood-2005-
03-1159. 
7. 
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of 
inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113(9):1271-
6. doi: 10.1172/JCI20945. 
8. 
Qiao B, Sugianto P, Fung E, Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T, Nemeth E. Hepcidin-induced 
endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab 2012;15(6):918-24. doi: 
10.1016/j.cmet.2012.03.018. 
9. 
Kong WN, Gao G, Chang YZ. Hepcidin and sports anemia. Cell Biosci 2014;4:19. doi: 10.1186/2045-3701-4-19. 
10. 
Nielsen HB, Secher NH, Christensen NJ, Pedersen BK. Lymphocytes and NK cell activity during repeated bouts 
of maximal exercise. Am J Physiol 1996;271(1 Pt 2):R222-7. doi: 10.1152/ajpregu.1996.271.1.R222. 
11. 
Ronsen O, Lea T, Bahr R, Pedersen BK. Enhanced plasma IL-6 and IL-1ra responses to repeated vs. single 
bouts of prolonged cycling in elite athletes. J Appl Physiol (1985) 2002;92(6):2547-53. doi: 
10.1152/japplphysiol.01263.2001. 
12. 
Peeling P, Dawson B, Goodman C, Landers G, Wiegerinck ET, Swinkels DW, Trinder D. Effects of exercise on 
hepcidin response and iron metabolism during recovery. Int J Sport Nutr Exerc Metab 2009;19(6):583-97. doi: 
10.1123/ijsnem.19.6.583. 
13. 
McClung JP, Karl JP, Cable SJ, Williams KW, Nindl BC, Young AJ, Lieberman HR. Randomized, double-blind, 
placebo-controlled trial of iron supplementation in female soldiers during military training: effects on iron status, 
physical performance, and mood. Am J Clin Nutr 2009;90(1):124-31. doi: 10.3945/ajcn.2009.27774. 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 27 of 39 
14. 
Pompano LM, Haas JD. Efficacy of iron supplementation may be misinterpreted using conventional measures 
of iron status in iron-depleted, nonanemic women undergoing aerobic exercise training. Am J Clin Nutr 
2017;106(6):1529-38. doi: 10.3945/ajcn.117.152777. 
15. 
Hennigar SR, McClung JP, Hatch-McChesney A, Allen JT, Wilson MA, Carrigan CT, Murphy NE, Teien HK, 
Martini S, Gwin JA, et al. Energy deficit increases hepcidin and exacerbates declines in dietary iron absorption 
following strenuous physical activity: a randomized-controlled cross-over trial. Am J Clin Nutr 2020. doi: 
10.1093/ajcn/nqaa289. 
16. 
Lundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol 2011;589(Pt 
6):1265-71. doi: 10.1113/jphysiol.2010.195917. 
17. 
Durussel J, Daskalaki E, Anderson M, Chatterji T, Wondimu DH, Padmanabhan N, Patel RK, McClure JD, 
Pitsiladis YP. Haemoglobin mass and running time trial performance after recombinant human erythropoietin 
administration in trained men. PLoS One 2013;8(2):e56151. doi: 10.1371/journal.pone.0056151. 
18. 
Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, Rasmussen P, Juel C, Lundby C. Prolonged 
administration of recombinant human erythropoietin increases submaximal performance more than maximal 
aerobic capacity. Eur J Appl Physiol 2007;101(4):481-6. doi: 10.1007/s00421-007-0522-8. 
19. 
Caillaud C, Connes P, Ben Saad H, Mercier J. Erythropoietin enhances whole body lipid oxidation during 
prolonged exercise in humans. J Physiol Biochem 2015;71(1):9-16. doi: 10.1007/s13105-014-0374-8. 
20. 
Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, Norgaard AM, Alberghini A, 
Campostrini N, Castagna A, et al. Alterations of systemic and muscle iron metabolism in human subjects 
treated with low-dose recombinant erythropoietin. Blood 2009;113(26):6707-15. doi: 10.1182/blood-2008-09-
178095. 
21. 
Hennigar SR, Gaffney-Stomberg E, Lutz LJ, Cable SJ, Pasiakos SM, Young AJ, McClung JP. Consumption of a 
calcium and vitamin D-fortified food product does not affect iron status during initial military training: a 
randomised, double-blind, placebo-controlled trial. Br J Nutr 2016;115(4):637-43. doi: 
10.1017/S0007114515004766. 
22. 
Annaheim S, Jacob M, Krafft A, Breymann C, Rehm M, Boutellier U. RhEPO improves time to exhaustion by 
non-hematopoietic factors in humans. Eur J Appl Physiol 2016;116(3):623-33. doi: 10.1007/s00421-015-3322-6. 
23. 
Wang L, Jia Y, Rogers H, Suzuki N, Gassmann M, Wang Q, McPherron AC, Kopp JB, Yamamoto M, Noguchi 
CT. Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1alpha and AMPK activation. 
Int J Biochem Cell Biol 2013;45(7):1155-64. doi: 10.1016/j.biocel.2013.03.007. 
24. 
Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, 
Boushel R. Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol 
2012;3:50. doi: 10.3389/fphys.2012.00050. 
25. 
Christensen B, Nellemann B, Thorsen K, Nielsen MM, Pedersen SB, Ornstrup MJ, JO JO, Jessen N. Prolonged 
erythropoietin treatment does not impact gene expression in human skeletal muscle. Muscle Nerve 
2015;51(4):554-61. doi: 10.1002/mus.24355. 
26. 
Larsen MS, Vissing K, Thams L, Sieljacks P, Dalgas U, Nellemann B, Christensen B. Erythropoietin 
administration alone or in combination with endurance training affects neither skeletal muscle morphology nor 
angiogenesis in healthy young men. Exp Physiol 2014;99(10):1409-20. doi: 10.1113/expphysiol.2014.080606. 
27. 
Lamon S, Zacharewicz E, Stephens AN, Russell AP. EPO-receptor is present in mouse C2C12 and human 
primary skeletal muscle cells but EPO does not influence myogenesis. Physiol Rep 2014;2(3):e00256. doi: 
10.1002/phy2.256. 
28. 
Mazzolari R, Papaioannou KG. Satellite cells: erythropoietin treatment and endurance training. J Physiol 
2016;594(18):5045-6. doi: 10.1113/JP272720. 
29. 
Lamon S, Russell AP. The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how 
much do we really know? Front Physiol 2013;4:176. doi: 10.3389/fphys.2013.00176. 
30. 
Margolis LM, Wilson MA, Whitney CC, Carrigan CT, Murphy NE, Hatch AM, Montain SJ, Pasiakos SM. 
Exercising with low muscle glycogen content increases fat oxidation and decreases endogenous, but not 
exogenous carbohydrate oxidation. Metabolism 2019;97:1-8. doi: 10.1016/j.metabol.2019.05.003. 
31. 
Hearris MA, Hammond KM, Seaborne RA, Stocks B, Shepherd SO, Philp A, Sharples AP, Morton JP, Louis JB. 
Graded reductions in preexercise muscle glycogen impair exercise capacity but do not augment skeletal muscle 
cell signaling: implications for CHO periodization. J Appl Physiol (1985) 2019;126(6):1587-97. doi: 
10.1152/japplphysiol.00913.2018. 
32. 
Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, Neufer PD. Transcriptional activation of 
the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 
2001;15(14):2748-50. doi: 10.1096/fj.01-0507fje. 
33. 
Connes P, Perrey S, Varray A, Prefaut C, Caillaud C. Faster oxygen uptake kinetics at the onset of submaximal 
cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 
2003;447(2):231-8. doi: 10.1007/s00424-003-1174-0. 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 28 of 39 
34. 
Lohman TG, Harris M, Teixeira PJ, Weiss L. Assessing body composition and changes in body composition. 
Another look at dual-energy X-ray absorptiometry. Ann N Y Acad Sci 2000;904:45-54. 
35. 
Fyfe CL, Stewart J, Murison SD, Jackson DM, Rance K, Speakman JR, Horgan GW, Johnstone AM. Evaluating 
energy intake measurement in free-living subjects: when to record and for how long? Public Health Nutr 
2010;13(2):172-80. doi: 10.1017/S1368980009991443. 
36. 
Jones AM, Doust JH. A 1% treadmill grade most accurately reflects the energetic cost of outdoor running. J 
Sports Sci 1996;14(4):321-7. doi: 10.1080/02640419608727717. 
37. 
Glass S, Gregory, B. . ACSM's Metabolic Calculations Handbook. Baltimore: Lippincott Williams & Wilkins, 
2007. 
38. 
Barringer ND, Pasiakos SM, McClung HL, Crombie AP, Margolis LM. Prediction equation for estimating total 
daily energy requirements of special operations personnel. J Int Soc Sports Nutr 2018;15:15. doi: 
10.1186/s12970-018-0219-x. 
39. 
ACMS' Guidelines for Exercise Testing and Prescription: Seventh Edition. 2006. 
40. 
Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy maximizes sample size. Med Sci Sports 
Exerc 1982;14(1):101-2. 
41. 
Pasiakos SM, McClung HL, McClung JP, Urso ML, Pikosky MA, Cloutier GJ, Fielding RA, Young AJ. Molecular 
responses to moderate endurance exercise in skeletal muscle. Int J Sport Nutr Exerc Metab 2010;20(4):282-90. 
42. 
Prommer N, Schmidt W. Loss of CO from the intravascular bed and its impact on the optimised CO-rebreathing 
method. Eur J Appl Physiol 2007;100(4):383-91. doi: 10.1007/s00421-007-0439-2. 
43. 
Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin 
mass routinely. Eur J Appl Physiol 2005;95(5-6):486-95. doi: 10.1007/s00421-005-0050-3. 
44. 
Wolfe RR, Chinkes DL. Isotope tracers in metabolic research: principles and practice of kinetic analysis: John 
Wiley & Sons, 2005. 
45. 
Jeukendrup AE, Wallis GA. Measurement of substrate oxidation during exercise by means of gas exchange 
measurements. Int J Sports Med 2005;26 Suppl 1:S28-37. doi: 10.1055/s-2004-830512. 
46. 
Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of circulating microRNA 
expression data obtained by quantitative real-time RT-PCR. Brief Bioinform 2016;17(2):204-12. doi: 
10.1093/bib/bbv056. 
47. 
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate 
normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. 
Genome Biol 2002;3(7):RESEARCH0034. 
48. 
Neves M, Jr., Barreto G, Boobis L, Harris R, Roschel H, Tricoli V, Ugrinowitsch C, Negrao C, Gualano B. 
Incidence of adverse events associated with percutaneous muscular biopsy among healthy and diseased 
subjects. Scand J Med Sci Sports 2012;22(2):175-8. doi: 10.1111/j.1600-0838.2010.01264.x. 
49. 
Highstead RG, Tipton KD, Creson DL, Wolfe RR, Ferrando AA. Incidence of associated events during the 
performance of invasive procedures in healthy human volunteers. J Appl Physiol (1985) 2005;98(4):1202-6. doi: 
01076.2004 [pii] 
10.1152/japplphysiol.01076.2004. 
 
 
 
 
SECTION E:  ABBREVIATIONS AND ACRONYMS 
See the “Guide for Investigators” 
 
Erythropietin; EPO, Hemoglobin; Hgb, Biomedical Performance Enhancement; BPE, Hematocrit; Hct, Office 
of Medical Support and Oversight; OMSO, prothrombin time; PT, partial thromboplastin time; PTT, mole 
percent excess; MPE, tracer to tracee ratio; TTR, Human Research Volunteer; HRV, 
 
 
 
SECTION F: DoD PRIVACY RULE AND PROTECTED HEALTH INFORMATION (HIPAA) 
Click in the appropriate box See the “Guide for Investigators” for definitions and further information.   
 
 NA – institution is not a covered entity 
 
 NA – will not use or disclose protected health information 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 29 of 39 
 
 HIPAA authorization will be obtained  
 
 An application for waiver/alteration of HIPAA authorization will be submitted   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A: Clinical Questionnaire 
 
Have you experienced in the last 24 hours any: 
1. Chest pain 
2. Shortness of breath 
3. Dizziness, lightheadedness, clamminess, diaphoresis (sweating), or fatigue  
4. Nausea, vomiting, belching, or indigestion 
5. Extremity swelling, pain, warmth, erythema 
6. Difficulty speaking, walking or understanding language 
7. Paralysis, numbness, or weakness of the face, arm, or leg 
8. Vision or hearing changes 
9. Headache 
10. Alteration in mental status (including, but not limited to confusion, memory loss, disorientation, or loss 
of alterness) 
11. Fever or chills 
12. Cough 
13. Itching 
14. Skin abnormalities to include, but not limited to rash or blistering 
15. Depression Symptoms: 
a. Depressed mood 
b. Loss of interest or pleasure 
c. Change in appetite or weight 
d. Sleep disturbance(s) 
e. Psychomotor disturbances (i.e. hand wringing, pacing, or fidgeting; slowness in body 
movements, thinking or speech) 
f. Feelings of worthlessness or guilt 
g. Thoughts about harming yourself or others 
 
 
 
 
 
 
 
 
 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 30 of 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B: Food Records 
 
Keeping Food Records 
GENERAL INSTRUCTIONS: 
 
 Record your food and beverage intake from midnight to midnight (24 hour) on each of the days on 
which you are asked to record your intake, for a total of three days. 
 
 Record everything you eat or drink.  Don’t forget to record all beverages, alcoholic beverages, snack 
foods, candy, etc.  Record items and amounts as soon as possible after eating to prevent memory error. 
 
 Write only one food or ingredient per line. Use more than one food record form for a day if necessary.  
 
 List all items added to food/drink (e.g., jelly, mustard, mayonnaise, margarine, sour cream, creamer, 
syrup).   
 
 Indicate if you removed anything from an item (ex. olives from salad, skin from chicken, etc) 
 
 Please record if you consumed any nutritional supplements.  Record the brand name and the nutrition 
information from the label or provide the product label or container with your record. 
 
FOOD OR BEVERAGE DESCRIPTION, BE SPECIFIC: 
 
 Record the restaurant or source where you got prepared food (e.g., Pizza Hut, Subway, PX, Dining 
Facility, cafeteria, vending machine, etc.). 
 
 Record the brand names of foods and beverages (e.g., Chips Ahoy mini chocolate chip cookies, Stouffer’s 
Macaroni & Cheese).  Please supply the product label if possible. 
 
 Record the type of food, (ex. white bread, 2% low fat milk, honey-roasted peanuts, fried chicken breast, 
bottled orange juice vs. orange drink, cake or raised doughnut). 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 31 of 39 
 
 Record how the food was prepared, (e.g., raw, baked, broiled, fried, sautéed, steamed, grilled, etc.). 
 
 If you ate something like PIZZA, specify the number of slices eaten as well as the number of slices in the 
entire pizza and the size of the entire pizza. 
EXAMPLE: Pepperoni pizza from Pizza Hut, 5 slices from a large (16”), 10-slice pizza. 
 
 List or describe the ingredients in unique dishes or combinations of foods, such as stews, casseroles, and 
salads.   
EXAMPLE: Lasagna (per piece)- lean ground beef (1/4 cup), mozzarella cheese (1 oz), ricotta cheese (1oz), 
tomato sauce (½ cup), 2 noodles. If food is home cooked, please provide recipe information on a separate 
sheet. 
 
AMOUNT CONSUMED: 
 
 Record the size of the bag, box, bottle, or restaurant order. Use the package weight on the label or menu 
information. (e.g., 1-lb bag of M&Ms; 20 fl. oz. or 2 liter bottle Coke, McDonalds jumbo fries).  Don’t 
confuse fluid ounces (fl. oz.) with weight ounces (oz.). 
 
 Specify the quantity or proportion of foods/beverages consumed (ex, 3 10-oz Bud Lite drafts; 1/2 of a 16-
oz bag of Baked Ruffles; 15 Ritz crackers; half 16-oz porterhouse steak, 1/6 of 9"diameter pie). 
 
 Count number of pieces (ex., 6 chicken nuggets). 
 
 Report amount in household measures (cup, fl. oz., Tbsp, tsp).  Actually measure if possible or use the 
tips sheet to visually estimate.  
 
 Measure the dimensions thickness, length, and width if possible (ex., baked potato—4" x 3").   
 
 Use your hand:  Fist = 1 cup, Palm of hand = 3oz meat, Golf ball = 2 Tablespoon. 
 
Helpful Hint: It’s easier, and your food record will be more accurate, if you write everything down as it is 
happening.  Don’t wait until the end of the day to record everything, because you’ll forget the specifics.  
Sample Food Record 
Approximate  
Time                
Food/Drink Item 
Method of 
Preparation 
Description/ Brand 
Name 
Amount 
11:00 AM 
Eggs Sandwich made with: 
 
” 
Toasted Bagel, Plain, Lender’s original 
1 
” 
scrambled eggs, in pan with cooking spray 
2 eggs 
” 
ketchup 
 
 
1 Tablespoon 
11:00 AM 
Orange Juice 
Tropicana 
1.5 Cups 
3:00 PM 
Chocolate chip cookies 
Chips Ahoy 
3 
4:30 PM 
Cheeseburger w/ bun 
McDonald’s 
1 
” 
Ketchup + Mustard 
 
        “  
1 packet of each 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 32 of 39 
” 
Medium Fries 
 
McDonald’s 
1 
” 
Vanilla shake 
 
McDonald’s 
¾ of 1 large 
7:00 PM 
Vanilla Ice cream 
 
Haagen-Dazs 
1 cup 


Protocol Title: Impact of erythropoietin on hematological adaptations and physical performance 
Date: 24 August  2022 
 
Date: HQ USAMRDC IRB Research Protocol Template v20September 2018  DO NOT TOUCH FOOTERS (THIS IS OURS AND HEADERS ARE YOURS) 
                   Page 33 of 39 
Volunteer ID: _________    Date:__________ 
 
 
 
 
 
 
 
 
 
Study Day # _______ 
*Record 1 day of records per double sided sheet* 
Time 
Meal 
Food/Drink Item 
Description 
Amount 
Place 
 
B-Breakfast 
L-Lunch 
D-Dinner 
S-Snack 
One item per line. Skip line between each 
meal or snack 
Be specific. Give details such as brand 
name, cooking method, etc. Attach 
recipes or food labels if applicable.  
Specify oz., 
cup, tsp, 
Tbsp, etc. 
Barracks, 
DFAC, 
restaurant 
(give name) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
Appendix C: Activity Log 
 
Training Log Instructions: 
 
Guidelines: 
 
I. 3-Day Training Log: 
 
 Record your purposeful exercise each day for 3 days on the Training Log 
provided.   
 Be specific about the type of exercise 
o Cardio… 
 What type of cardio did you do? 
 How long did you work out? 
 How far did you go?   
 Did you do the activity continuously, or did you rest during? 
o Resistance… 
 What muscle groups did you work? 
 How many sets did you do?  How many repetitions per set?   
 How long was the rest time between sets?   
 Use the Weeklong Training Log Entry Example below as a guide. 
 
II. What/When to Return: 
 
 Return completed log as directed.   
 
                                       Example of Training Log Entry 
Day/Date: 
  
Time 
Type/Description of Activity 
Time/Distance/Reps 
7:45 AM 
Ran 
3.0 miles in            
27 min 30 sec. 
8:15 AM 
Weight Lifted - Chest & Back 
45 min total:           
4 exercises/muscle 
group, 8 repetitions/set 
(exercise),             
1 min rest between sets 
 
Helpful Hints:  
1. Don't change your exercise habits.  This should be an accurate description of your typical 
physical activity.  
2. It’s easier, and your activity record will be more accurate, if you write everything down 
as it is happening.  Don’t wait until the end of the day to record everything, because 
you’ll forget the specifics.   
3. Call if you have any questions or concerns  


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
 
Date:__________________ 
Time 
Type/Description of Activity 
Time/Distance/Reps 
  
  
  
  
  
  
  
  
  
  
  
  
 
Date:__________________ 
Time 
Type/Description of Activity 
Time/Distance/Reps 
  
  
  
  
  
  
  
  
  
  
  
  
 
                                                       Date:__________________ 
Time 
Type/Description of Activity 
Time/Distance/Reps 
  
  
  
  
  
  
  
  
  
  
  
  
 
 


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
Appendix D: Muscle Biopsy Care 
 
Muscle Biopsy Care 
Information for the Participant 
 
You have just had a percutaneous muscle biopsy. The muscle biopsy site is closed with 
a steri-strip. This is covered with 4 x 4 gauze pad, a transparent dressing to prevent the 
incision from getting wet, and an elastic ACE bandage. 
 
As the anesthetic wears off, you may feel a dull ache at the biopsy site for ~1-3 days. 
Many people have no pain at all. Instructions for the care of the biopsy site are as 
follows: 
 
1. You may perform all your normal activities immediately after the biopsy, including 
light exercise. 
 
2. Leave the ACE bandage in place for 5 hours after the biopsy. After this time, 
remove the elastic bandage. The following morning, the biopsy site will be 
examined by the study principal investigator or the US Army Research Institute of 
Environmental Medicine (USARIEM) Office of Medical Support and Oversight 
(OMSO). The principal investigator or OMSO will remove the transparent 
dressing and gauze pad.  
 
3. An appointment will be scheduled with OMSO within 3 d of your procedure to 
ensure proper healing.  
 
4. Do not take any aspirin or aspirin-containing products for 5 days after the biopsy 
unless the OMSO MD/PA approves. Also avoid ‘aspirin-like’ drugs such as 
Motrin, Indocin, etc. Tylenol is OK. 
 
5. After 2 days, no special precautions are required and the site should be almost 
completely healed. 
 
6. If any of the signs below occur, please contact the study principal investigator: 
 
– Fever 
– Bleeding from biopsy site 
– Inflammation at biopsy site (warmth, redness, tenderness, pus 
formation, clear discharge, opening of incision, lump under incision, or 
rash around incision) 
– If you are not sure if it is healing normally, alert the study principal 
investigator who will direct you to on duty medical staff 
– Persistent numbness in the leg 
– Pain at the biopsy site more than one week after the biopsy 
 
 
 
 


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
Appendix E: Photo Release Form 
US ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE 
 
Audio/Visual Image Release* 
*Only complete this form if you are willing to be photographed or recorded for 
some or for all of the below-described purposes.                                        
We are asking your permission to take photographs, videotape, or digital video 
recordings of you during your participation in the study titled, Erythropoietin induced 
hematological adaptations to enhance physical performance. 
Please note you may be permitting researchers to use and keep your images despite 
Consent Form language that your identity would otherwise remain anonymous and that 
records will be destroyed 
For Project Illustration and Presentation at Academic Conferences, I grant 
permission to be photographed or otherwise visually recorded during this study even if 
someone could recognize me: Please initial one 
Yes _______  
No _______  
Please note you may be permitting researchers to use and keep your images despite 
Consent Form language that your identity would otherwise remain anonymous and that 
records will be destroyed 
For Marketing, Posting Online, and Public Affairs, I grant permission to be 
photographed or otherwise visually recorded during this study, 
 
     
 
 
 
 
 
 Initials 
 
 
Even if someone could recognize me. ______ 
If you agree, initial one OR  
 
 
 
OR 
 
 
 
 
      
the other (otherwise leave 
Provided that I cannot be recognized. ______  
blank) 
Can we use your name? 
I grant permission for my name to be on a photo or video image of me or in writing 
connected to my image. 
 
 
 
 
 
 
 
Initials 
 
Yes   
______ 
 
OR                                     Initial one OR the other 
 
No     
______ 
I understand that I will not be paid or otherwise compensated for the use of my image. 
1. Participant 
Typed or printed name (Last, first, 
middle initial)  
Signature 
 
Date(YYYYM
MDD) 
2. Witness 


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
Typed or printed name (Last, first, 
middle initial)  
Signature 
Date(YYYYM
MDD) 
 
 
 
 
 


Lee Margolis, PhD: Erythropoietin induced hematological adaptations to enhance physical performance 
 
Version date: 30 Oct 2018 
Appendix F: Study Timeline